<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Disulfiram for the treatment of cocaine dependence - Traccis, F - 2024 | Cochrane Library</title> <meta content="Disulfiram for the treatment of cocaine dependence - Traccis, F - 2024 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007024.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Disulfiram for the treatment of cocaine dependence - Traccis, F - 2024 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007024.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007024.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Disulfiram for the treatment of cocaine dependence" name="citation_title"/> <meta content="Francesco Traccis&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="University of Cagliari" name="citation_author_institution"/> <meta content="Silvia Minozzi&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Lazio Regional Health Service" name="citation_author_institution"/> <meta content="Emanuela Trogu" name="citation_author"/> <meta content="Psychiatric Diagnosis and Treatment Service, Local Social Health Agency" name="citation_author_institution"/> <meta content="Rosangela Vacca" name="citation_author"/> <meta content="ARES Sardegna" name="citation_author_institution"/> <meta content="Simona Vecchi" name="citation_author"/> <meta content="Lazio Regional Health Service" name="citation_author_institution"/> <meta content="Pier Paolo Pani" name="citation_author"/> <meta content="Sardinia Protection Health Trust" name="citation_author_institution"/> <meta content="Roberta Agabio" name="citation_author"/> <meta content="University of Cagliari" name="citation_author_institution"/> <meta content="agabio@unica.it" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD007024.pub3" name="citation_doi"/> <meta content="2024" name="citation_date"/> <meta content="2024/01/05" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007024.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007024.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007024.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Alcoholism [drug therapy]; *Cocaine; *Cocaine-Related Disorders [drug therapy]; Disulfiram [adverse effects]; Naltrexone" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007024.pub3&amp;doi=10.1002/14651858.CD007024.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007024.pub3&amp;doi=10.1002/14651858.CD007024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007024.pub3&amp;doi=10.1002/14651858.CD007024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007024.pub3&amp;doi=10.1002/14651858.CD007024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007024.pub3&amp;doi=10.1002/14651858.CD007024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007024.pub3&amp;doi=10.1002/14651858.CD007024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007024.pub3&amp;doi=10.1002/14651858.CD007024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007024.pub3&amp;doi=10.1002/14651858.CD007024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007024.pub3&amp;doi=10.1002/14651858.CD007024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007024.pub3&amp;doi=10.1002/14651858.CD007024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007024.pub3&amp;doi=10.1002/14651858.CD007024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007024.pub3&amp;doi=10.1002/14651858.CD007024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007024.pub3&amp;doi=10.1002/14651858.CD007024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007024.pub3&amp;doi=10.1002/14651858.CD007024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007024.pub3&amp;doi=10.1002/14651858.CD007024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007024.pub3&amp;doi=10.1002/14651858.CD007024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007024.pub3&amp;doi=10.1002/14651858.CD007024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007024.pub3&amp;doi=10.1002/14651858.CD007024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007024.pub3&amp;doi=10.1002/14651858.CD007024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007024.pub3&amp;doi=10.1002/14651858.CD007024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007024.pub3&amp;doi=10.1002/14651858.CD007024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007024.pub3&amp;doi=10.1002/14651858.CD007024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007024.pub3&amp;doi=10.1002/14651858.CD007024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="qy4lqFNF";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007024\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007024\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007024\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007024\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","ru","ko","pt","th","ms","ja","fa","id","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007024.pub3",title:"Disulfiram for the treatment of cocaine dependence",firstPublishedDate:"Jan 5, 2024 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Drugs and Alcohol Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=qy4lqFNF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007024.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007024.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007024.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007024.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007024.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007024.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;id&quot;,&quot;title&quot;:&quot;Saripati tinjauan sistematik&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007024.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007024.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007024.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007024.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1672 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007024.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007024.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007024.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007024.pub3/full#CD007024-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007024.pub3/full#CD007024-sec-0109"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007024.pub3/full#CD007024-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007024.pub3/full#CD007024-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007024.pub3/full#CD007024-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007024.pub3/full#CD007024-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007024.pub3/full#CD007024-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007024.pub3/full#CD007024-sec-0101"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007024.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007024.pub3/appendices#CD007024-sec-0114"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007024.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007024.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/supinfo/CD007024-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/supinfo/CD007024-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007024.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007024.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007024.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007024.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007024.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007024.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Disulfiram for the treatment of cocaine dependence</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="These authors should be considered joint first author"><a href="/cdsr/doi/10.1002/14651858.CD007024.pub3/information#CD007024-cr-0004">Francesco Traccis</a><sup>a</sup></li> <li class="author custom-tooltip" title="These authors should be considered joint first author"><a href="/cdsr/doi/10.1002/14651858.CD007024.pub3/information#CD007024-cr-0005">Silvia Minozzi</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007024.pub3/information#CD007024-cr-0006">Emanuela Trogu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007024.pub3/information#CD007024-cr-0007">Rosangela Vacca</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007024.pub3/information#CD007024-cr-0008">Simona Vecchi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007024.pub3/information#CD007024-cr-0009">Pier Paolo Pani</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007024.pub3/information#CD007024-cr-0010"><i class="icon corresponding-author fa fa-envelope"></i>Roberta Agabio</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/information/en#CD007024-sec-0125">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 05 January 2024 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007024.pub3">https://doi.org/10.1002/14651858.CD007024.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007024-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007024-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007024-abs-0019">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007024-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007024-abs-0016">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD007024-abs-0005">한국어</a> </li> <li class="section-language"> <a class="" href="full/pt#CD007024-abs-0007">Português</a> </li> <li class="section-language"> <a class="" href="full/th#CD007024-abs-0009">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007024-abs-0001" lang="en"> <section id="CD007024-sec-0001"> <h3 class="title" id="CD007024-sec-0001">Background</h3> <p>Cocaine is a psychostimulant used by approximately 0.4% of the general population worldwide. Cocaine dependence is a chronic mental disorder characterised by the inability to control cocaine use and a host of severe medical and psychosocial complications. There is current no approved pharmacological treatment for cocaine dependence. Some researchers have proposed disulfiram, a medication approved to treat alcohol use disorder. </p> <p>This is an update of a Cochrane review first published in 2010.</p> </section> <section id="CD007024-sec-0002"> <h3 class="title" id="CD007024-sec-0002">Objectives</h3> <p>To evaluate the efficacy and safety of disulfiram for the treatment of cocaine dependence.</p> </section> <section id="CD007024-sec-0003"> <h3 class="title" id="CD007024-sec-0003">Search methods</h3> <p>We updated our searches of the following databases to August 2022: the Cochrane Drugs and Alcohol Group Specialised Register, CENTRAL, MEDLINE, Embase, CINAHL, and PsycINFO. We also searched for ongoing and unpublished studies via two trials registries. We handsearched the references of topic‐related systematic reviews and included studies. The searches had no language restrictions. </p> </section> <section id="CD007024-sec-0004"> <h3 class="title" id="CD007024-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials that evaluated disulfiram alone or associated with psychosocial interventions versus placebo, no intervention, other pharmacological interventions, or any psychosocial intervention for the treatment of cocaine dependence. </p> </section> <section id="CD007024-sec-0005"> <h3 class="title" id="CD007024-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane.</p> </section> <section id="CD007024-sec-0006"> <h3 class="title" id="CD007024-sec-0006">Main results</h3> <p>Thirteen studies (1191 participants) met our inclusion criteria.</p> <p><b>Disulfiram versus placebo or no treatment</b> </p> <p>Disulfiram compared to placebo may increase the number of people who are abstinent at the end of treatment (point abstinence; risk ratio (RR) 1.58, 95% confidence interval (CI) 1.05 to 2.36; 3 datasets, 142 participants; low‐certainty evidence). However, compared to placebo or no pharmacological treatment, disulfiram may have little or no effect on frequency of cocaine use (standardised mean difference (SMD) −0.11 standard deviations (SDs), 95% CI −0.39 to 0.17; 13 datasets, 818 participants), amount of cocaine use (SMD −0.00 SDs, 95% CI −0.30 to 0.30; 7 datasets, 376 participants), continuous abstinence (RR 1.23, 95% CI 0.80 to 1.91; 6 datasets, 386 participants), and dropout for any reason (RR 1.20, 95% CI 0.92 to 1.55; 14 datasets, 841 participants). The certainty of the evidence was low for all these outcomes. We are unsure about the effects of disulfiram versus placebo on dropout due to adverse events (RR 12.97, 95% CI 0.77 to 218.37; 1 study, 67 participants) and on the occurrence of adverse events (RR 3.00, 95% CI 0.35 to 25.98), because the certainty of the evidence was very low for these outcomes. </p> <p><b>Disulfiram versus naltrexone</b> </p> <p>Disulfiram compared with naltrexone may reduce the frequency of cocaine use (mean difference (MD) −1.90 days, 95% CI −3.37 to −0.43; 2 datasets, 123 participants; low‐certainty evidence) and may have little or no effect on amount of cocaine use (SMD 0.12 SDs, 95% CI −0.27 to 0.51, 2 datasets, 123 participants; low‐certainty evidence). We are unsure about the effect of disulfiram versus naltrexone on dropout for any reason (RR 0.86, 95% CI 0.56 to 1.32, 3 datasets, 131 participants) and dropout due to adverse events (RR 0.50, 95% CI 0.07 to 3.55; 1 dataset, 8 participants), because the certainty of the evidence was very low for these outcomes. </p> </section> <section id="CD007024-sec-0007"> <h3 class="title" id="CD007024-sec-0007">Authors' conclusions</h3> <p>Our results show that disulfiram compared to placebo may increase point abstinence. However, disulfiram compared to placebo or no pharmacological treatment may have little or no effect on frequency of cocaine use, amount of cocaine use, continued abstinence, and dropout for any reason. We are unsure if disulfiram has any adverse effects in this population. Caution is required when transferring our results to clinical practice. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007024-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007024-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007024-abs-0020">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007024-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007024-abs-0017">Français</a> </li> <li class="section-language"> <a class="" href="full/id#CD007024-abs-0015">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="full/ja#CD007024-abs-0012">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD007024-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD007024-abs-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD007024-abs-0018">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD007024-abs-0008">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD007024-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD007024-abs-0010">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD007024-abs-0003">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007024-abs-0002" lang="en"> <h3>Disulfiram as a medication for the treatment of cocaine dependence</h3> <p><b>Key messages</b> </p> <p>• In people with cocaine dependence, disulfiram compared to placebo may increase the number of people who are abstinent at the end of treatment, but may have little or no effect on the frequency and amount of cocaine use and on the number of people who have achieved and maintained abstinence for at least three weeks at the end of treatment. We are unsure if disulfiram has any unwanted effects in people with cocaine dependence. </p> <p>• In people with cocaine dependence, disulfiram compared to naltrexone may reduce the frequency of cocaine use but may have little or no effect on the amount of cocaine use. </p> <p>• Of the 13 studies included in our review, 11 took place in the USA. Furthermore, most people included in the studies were men. Our results may not be applicable in other contexts because the effects of treatment could be strongly influenced by social environment, ethnicity, and sex. </p> <p><b>What is cocaine dependence?</b> </p> <p>Cocaine is one of the most commonly used psychostimulants worldwide. Psychostimulants are medicines or illegal drugs that stimulate the nervous system and have mood‐enhancing properties. The latest estimates indicate that more than 0.4% of adults have used cocaine at least once in the past year. </p> <p>Cocaine use is associated with medical, psychological, and social problems, including the spread of infectious diseases (e.g. AIDS, hepatitis, tuberculosis), crime, violence, and drug exposure during pregnancy. Cocaine use can increase the risk of HIV infection through high‐risk injecting and sexual behaviours. </p> <p>Cocaine dependence is a severe mental disorder characterised by an intense desire to use cocaine and inability to control cocaine use, causing people to use larger amounts than they intended. </p> <p><b>How is cocaine dependence treated?</b> </p> <p>Cocaine dependence is usually treated with psychosocial treatments. No effective pharmacological treatments are available. Studies have evaluated whether a medication called disulfiram could help people with cocaine dependence. Disulfiram is currently used to treat people with alcohol dependence. It works by causing unpleasant physical reactions if the person drinks alcohol. </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to find out whether disulfiram can help people with cocaine dependence reduce their cocaine use or stop using cocaine altogether. We also wanted to know whether treatment with disulfiram was acceptable and safe for people with cocaine dependence. </p> <p><b>What did we do?</b> </p> <p>We searched thoroughly for randomised studies (where people were allocated at random to one of two or more treatment groups) comparing disulfiram with no medicines, placebo (dummy treatment), or other medicines. </p> <p>We compared and summarised the results and rated our confidence in the evidence, based on factors such as methods and precision of the results of each study. </p> <p><b>What did we find?</b> </p> <p>We found 13 studies, which enroled 1191 people with cocaine dependence. The average duration of treatment was about three months. Twelve studies compared disulfiram with placebo or no pharmacological treatment, and three studies compared disulfiram with naltrexone (a medicine used to treat people with alcohol dependence or opioid dependence). </p> <p><b>Main results</b> </p> <p>Disulfiram compared with placebo may increase the number of people who are not using cocaine at the end of treatment, but may have little or no effect on the frequency of cocaine use (number of days or weeks of cocaine use at the end of treatment), the amount of cocaine use (weight of cocaine used or money spent on cocaine at the end of treatment), the number of people who achieve and maintain abstinence for at least three weeks, and the number of people who prematurely interrupt the treatment. We are unsure if disulfiram has any unwanted effects in people with cocaine addiction. </p> <p>Disulfiram compared with naltrexone may decrease the frequency of cocaine use but may have little or no effect on the amount of cocaine use or on the number of people who prematurely interrupt treatment. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>We cannot be sure that the studies allocated people to groups appropriately, as most studies did not describe this process in detail. </p> <p>There were important variations in the characteristics of the people included in the studies: some had additional substance use disorders, some were using other medicines, and some were receiving other psychosocial treatments. </p> <p>In addition, most people included in the studies were men, and 11 of the 13 studies took place in the USA. Therefore, our results may not apply to women or people living in other countries. </p> <p><b>How up to date is this evidence</b>? </p> <p>This review updates our previous review. The evidence is up to date to August 2022.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007024-sec-0109" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007024-sec-0109"></div> <h3 class="title" id="CD007024-sec-0110">Implications for practice</h3> <section id="CD007024-sec-0110"> <p>Our results show that disulfiram compared to placebo may increase point abstinence (the proportion of people who are abstinent at the end of treatment). However, disulfiram compared to placebo or no pharmacological treatment may have little or no effect on frequency of cocaine use, amount of cocaine use, continued abstinence, and dropout for any reason. We are unsure if disulfiram has any adverse effects in people with cocaine dependence. Caution is required when transferring our results to clinical practice. </p> </section> <h3 class="title" id="CD007024-sec-0111">Implications for research</h3> <section id="CD007024-sec-0111"> <p>Larger studies are needed to confirm our results. Future studies should investigate the efficacy and safety profile of disulfiram in specific categories of people with cocaine dependence, such as women, people with other substance use disorders, people co‐treated with other medications (methadone, buprenorphine), and people receiving specific psychosocial interventions. Conducting future studies in countries other than the USA would increase the generalisability of the evidence. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007024-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007024-sec-0008"></div> <div class="table" id="CD007024-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table – disulfiram compared to placebo or no pharmacological treatment for people with cocaine dependence</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Disulfiram compared to placebo or no pharmacological treatment for people with cocaine dependence</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> people with cocaine dependence<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> disulfiram<br/><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(datasets; studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo or no treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with disulfiram</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Frequency of cocaine use</b> (mean number of days or weeks of cocaine use at the end of treatment) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>SMD 0.11 SDs lower</b><br/>(0.39 lower to 0.17 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>818<br/>(13 datasets; 9 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Amount of cocaine use</b> (mean weight of cocaine used or money spent on cocaine at the end of treatment) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>SMD 0 SDs</b><br/>(0.3 lower to 0.3 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>376<br/>(7 datasets; </p> <p>5 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Continuous abstinence from cocaine</b> (number of participants who had achieved and maintained abstinence for at least three weeks at the end of treatment) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>245 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>301 per 1000</b><br/>(196 to 467) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.23</b><br/>(0.80 to 1.91) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>386<br/>(6 datasets; </p> <p>5 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Point abstinence</b> (number of participants who were abstinent at the end of the treatment) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>309 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>488 per 1000</b><br/>(324 to 729) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.58</b><br/>(1.05 to 2.36) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142<br/>(3 datasets; </p> <p>2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dropout for any reason</b> (number of participants who did not complete treatment) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>273 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>328 per 1000</b><br/>(251 to 423) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.20</b><br/>(0.92 to 1.55) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>841<br/>(14 datasets; </p> <p>10 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dropout due to adverse events</b> (number of participants who did not complete treatment due to adverse events) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 12.97</b><br/>(0.77 to 218.37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/>(1 dataset; </p> <p>1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any adverse events</b> (number of participants who experienced at least one adverse event) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>67 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b><br/>(23 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.00</b><br/>(0.35 to 25.68) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 dataset; </p> <p>1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>e</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SD:</b> standard deviation; <b>SMD:</b> standardised mean difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level for risk of bias (all or most studies at unclear risk of bias for allocation concealment) and one level for inconsistency (I<sup>2</sup> = 72%; Chi<sup>2</sup> = 89.2%, P = 0.002).<br/><sup>b</sup> Downgraded one level for risk of bias (all or most studies at unclear risk of bias for allocation concealment) and one level for imprecision (fewer than 400 participants).<br/><sup>c</sup> Downgraded one level for risk of bias (all or most studies at unclear risk of bias for allocation concealment) and one level for imprecision (optimal information size not met).<br/><sup>d</sup> Downgraded one level for risk of bias (unclear risk of selection bias) and two levels for imprecision (single study with 67 participants).<br/><sup>e</sup> Downgraded one level for risk of bias (unclear risk of selection bias) and two levels for imprecision (single study with 30 participants). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007024-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings table – disulfiram compared to naltrexone for people with cocaine dependence</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Disulfiram compared to naltrexone for people with cocaine dependence</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> people with cocaine dependence<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> disulfiram<br/><b>Comparison:</b> naltrexone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Naltrexone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Disulfiram</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Frequency of cocaine use</b> (mean number of days or weeks of cocaine use at the end of treatment) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean frequency of cocaine use was <b>0 days</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 1.9 days fewer</b><br/>(3.37 fewer to 0.43 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Amount of cocaine use</b> (mean weight of cocaine used or money spent on cocaine at the end of treatment) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>SMD 0.12 SDs higher</b><br/>(0.27 lower to 0.51 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Continuous abstinence from cocaine</b> (number of participants who had achieved and maintained abstinence for at least three weeks at the end of treatment) </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Point abstinence</b> (number of participants who were abstinent at the end of the treatment) </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dropout for any reason</b> (number of participants who did not complete treatment) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>415 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>357 per 1000</b><br/>(233 to 548) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.86</b><br/>(0.56 to 1.32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dropout due to adverse events</b> (number of participants who did not complete treatment due to adverse events) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>250 per 1000</b><br/>(35 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.50</b><br/>(0.07 to 3.55) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any adverse events</b> (number of participants who experienced at least one adverse event) </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SD:</b> standard deviation; <b>SMD:</b> standardised mean difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level for risk of bias (both studies at unclear risk of selection bias) and one level for imprecision (fewer than 400 participants).<br/><sup>b</sup> Downgraded one level for risk of bias (two studies at high risk of performance and detection bias; all three studies at unclear risk of selection bias) and two levels for imprecision (fewer than 100 events). <br/><sup>c</sup> Downgraded one level for risk of bias (unclear risk of selection bias) and two levels for imprecision (fewer than 100 events). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007024-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD007024-sec-0009"></div> <section id="CD007024-sec-0010"> <h3 class="title" id="CD007024-sec-0010">Description of the condition</h3> <p>Cocaine is an alkaloid derived from the leaf of erythroxylon coca. Cocaine is commonly snorted or injected as powder or smoked as crack, a freebase form. Cocaine dependence is a major public health problem, characterised by recidivism and a host of medical and psychosocial complications (<a href="./references#CD007024-bbs2-0053" title="European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2022: Trends and Developments. Publications Office of the European Union, Luxembourg. www.emcdda.europa.eu/system/files/publications/14644/EDR_2022_18-ONLINE.pdf.">EMCDDA 2022</a>). Another name for cocaine dependence is cocaine use disorder (<a href="./references#CD007024-bbs2-0050" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. American Psychiatric Association, 2013.">DSM‐5</a>). </p> <p>Acute and chronic use of cocaine is associated with a wide and well‐documented range of medical, psychological, and social problems, including the spread of infectious diseases (e.g. AIDS, hepatitis, tuberculosis), crime, violence, and neonatal drug exposure (<a href="./references#CD007024-bbs2-0055" title="FarrellM , MartinNK , StockingsE , BórquezA , CepedaJA , DegenhardtL , et al. Responding to global stimulant use: challenges and opportunities. Lancet2019;394(10209):1652-67. [DOI: 10.1016/S0140-6736(19)32230-5]">Farrell 2019</a>). Cocaine use can increase the risk of HIV infection through high risk injecting and sexual behaviours (<a href="./references#CD007024-bbs2-0055" title="FarrellM , MartinNK , StockingsE , BórquezA , CepedaJA , DegenhardtL , et al. Responding to global stimulant use: challenges and opportunities. Lancet2019;394(10209):1652-67. [DOI: 10.1016/S0140-6736(19)32230-5]">Farrell 2019</a>). </p> <p>The illicit use of cocaine has become a persistent health problem worldwide. According to the United Nations Office on Drugs and Crime, 21.5 million people (or 0.4% of the global population aged 15 to 64 years) used cocaine at least once in 2020 (<a href="./references#CD007024-bbs2-0100" title="UN Office on Drugs and Crime. World Drug Report 2022. www.unodc.org/unodc/en/data-and-analysis/world-drug-report-2022.html2022.">UNOCD 2022</a>); the highest prevalence levels were found in Oceania (2.7%), North America (2.0%), Western and Central Europe (1.4%), and South America (1.6%). The prevalence of use among young adults (aged 18 to 25 years) may be higher than the population average (<a href="./references#CD007024-bbs2-0091" title="RyanSA . Cocaine use in adolescents and young adults. Pediatric Clinics of North America2019;66(6):1135-47.">Ryan 2019</a>). For example, 6.2% of young adults in the USA reported past‐year use of cocaine or crack cocaine in 2017 (<a href="./references#CD007024-bbs2-0092" title="BoseJ , HeddenSR , LipariRN , Park-LeeE . Key substance use and mental health indicators in the United States: results from the 2017 national survey on drug use and health. Substance Abuse and Mental Health Services Administration (SAMHSA), U.S. Department of Health and Human Services (HHS), 2018. www.samhsa.gov/data/sites/default/files/cbhsq-reports/NSDUHFFR2017/NSDUHFFR2017.pdf.">SAMHSA 2018</a>). </p> <p>In 2016, the global age‐standardised prevalence of cocaine use disorder was estimated at 77.6 (range 70.7 to 85.9) per 100,000 population, with higher values in men (105.5 per 100,000; range 96.3 to 116.3) than in women (49.4 per 100,000; range 44.7 to 54.9; <a href="./references#CD007024-bbs2-0057" title="GBD 2016 Alcohol and Drug Use Collaborators. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry2018;5(12):987-1012. [DOI: 10.1016/S2215-0366(18)30337-7]">GBD 2018</a>). As women account for approximately one in three people with cocaine use disorder, treatment services should consider their specific needs (<a href="./references#CD007024-bbs2-0078" title="MotykaMA , Al-ImamA , HaligowskaA , MichalakM . Helping women suffering from drug addiction: needs, barriers, and challenges. International Journal of Environmental Research and Public Health2022;19(21):14039. [DOI: 10.3390/ijerph192114039]">Motyka 2022</a>). However, most people with cocaine use disorder have little contact with treatment services (<a href="./references#CD007024-bbs2-0055" title="FarrellM , MartinNK , StockingsE , BórquezA , CepedaJA , DegenhardtL , et al. Responding to global stimulant use: challenges and opportunities. Lancet2019;394(10209):1652-67. [DOI: 10.1016/S0140-6736(19)32230-5]">Farrell 2019</a>). One study estimated that from 2015 to 2018, only 10.6% of adults with substance use disorder (SUD) in the USA received treatment, and this proportion was similar in men and women (<a href="./references#CD007024-bbs2-0072" title="MartinCE , Parlier-AhmadAB , BeckL , ScialliA , TerplanM . Need for and receipt of substance use disorder treatment among adults, by gender, in the United States. Public Health Reports2022;137(5):955-63. [DOI: 10.1177/00333549211041554]">Martin 2022</a>). Among people who expressed a need for SUD treatment, only one‐fifth received it (20.1%, 95% CI 16.7% to 23.4%; <a href="./references#CD007024-bbs2-0072" title="MartinCE , Parlier-AhmadAB , BeckL , ScialliA , TerplanM . Need for and receipt of substance use disorder treatment among adults, by gender, in the United States. Public Health Reports2022;137(5):955-63. [DOI: 10.1177/00333549211041554]">Martin 2022</a>). </p> </section> <section id="CD007024-sec-0011"> <h3 class="title" id="CD007024-sec-0011">Description of the intervention</h3> <p>There is currently no pharmacological treatment of proved efficacy for cocaine dependence, although considerable advances in the neurobiology of this mental disorder could guide future medication development (<a href="./references#CD007024-bbs2-0055" title="FarrellM , MartinNK , StockingsE , BórquezA , CepedaJA , DegenhardtL , et al. Responding to global stimulant use: challenges and opportunities. Lancet2019;394(10209):1652-67. [DOI: 10.1016/S0140-6736(19)32230-5]">Farrell 2019</a>). Several Cochrane reviews have evaluated the efficacy of different drugs on cocaine dependence: antidepressants (<a href="./references#CD007024-bbs2-0069" title="LimaMS , ReisserAA , SoaresBGO , FarrellM . Antidepressants for cocaine dependence. Cochrane Database of Systematic Reviews2003, Issue 2. Art. No: CD002950. [DOI: 10.1002/14651858.CD002950]">Lima 2003</a>; <a href="./references#CD007024-bbs2-0084" title="PaniPP , TroguE , VecchiS , AmatoL . Antidepressants for cocaine dependence and problematic cocaine use. Cochrane Database of Systematic Reviews2011, Issue 12. Art. No: CD002950. [DOI: 10.1002/14651858.CD002950.pub3]">Pani 2011</a>), antipsychotics (<a href="./references#CD007024-bbs2-0038" title="AmatoL , MinozziS , PaniPP , DavoliM . Antipsychotic medications for cocaine dependence. Cochrane Database of Systematic Reviews2007, Issue 3. Art. No: CD006306. [DOI: 10.1002/14651858.CD006306.pub2]">Amato 2007</a>; <a href="./references#CD007024-bbs2-0067" title="IndaveBI , MinozziS , PaniPP , AmatoL . Antipsychotic medications for cocaine dependence. Cochrane Database of Systematic Reviews2016, Issue 3. Art. No: CD006306. [DOI: 10.1002/14651858.CD006306.pub3]">Indave 2016</a>), anticonvulsants (<a href="./references#CD007024-bbs2-0075" title="MinozziM , AmatoL , PaniPP , VecchiS , DavoliM . Anticonvulsants for cocaine dependence. Cochrane Database of Systematic Reviews2008, Issue 2. Art. No: CD006754. [DOI: 10.1002/14651858.CD006754.pub2]">Minozzi 2008</a>; <a href="./references#CD007024-bbs2-0076" title="MinozziS , CinquiniM , AmatoL , DavoliM , FarrellMF , PaniPP , VecchiS . Anticonvulsants for cocaine dependence. Cochrane Database of Systematic Reviews2015, Issue 4. Art. No: CD006754. [DOI: 10.1002/14651858.CD006754.pub4]">Minozzi 2015a</a>), dopamine agonists (<a href="./references#CD007024-bbs2-0039" title="AmatoL , MinozziS , PaniPP , SoliminiR , VecchiS , Zuccaro P et al. Dopamine agonists for the treatment of cocaine dependence. Cochrane Database of Systematic Reviews2011, Issue 12. Art. No: CD003352. [DOI: 10.1002/14651858.CD003352.pub3]">Amato 2011</a>; <a href="./references#CD007024-bbs2-0077" title="MinozziS , AmatoL , PaniPP , SoliminiR , VecchiS , De Crescenzo F et al. Dopamine agonists for the treatment of cocaine dependence. Cochrane Database of Systematic Reviews2015, Issue 5. Art. No: CD003352. [DOI: 10.1002/14651858.CD003352.pub4]">Minozzi 2015b</a>; <a href="./references#CD007024-bbs2-0094" title="SoaresBG , LimaMS , ReisserAA , FarrellM . Dopamine agonists for cocaine dependence. Cochrane Database of Systematic Reviews2003, Issue 2. Art. No: CD003352. [DOI: 10.1002/14651858.CD003352]">Soares 2003</a>), and psychostimulant drugs (<a href="./references#CD007024-bbs2-0044" title="CastellsX , CunillR , Pérez-MañáC , VidalX , CapellàD . Psychostimulant drugs for cocaine dependence. Cochrane Database of Systematic Reviews2016, Issue 9(9). Art. No: CD007380. [DOI: 10.1002/14651858.CD007380.pub4] [PMID: 27670244]">Castells 2016</a>). However, no reviews have confirmed the efficacy of these treatments. Regarding psychosocial interventions, a systematic review published in 2021 found that only contingency management programmes significantly reduced cocaine use among adults (<a href="./references#CD007024-bbs2-0042" title="BentzleyBS , HanSS , NeunerS , HumphreysK , KampmanKM , HalpernCH . Comparison of treatments for cocaine use disorder among adults: a systematic review and meta-analysis. JAMA Network Open2021;4(5):e218049. [DOI: 10.1001/jamanetworkopen.2021.8049]">Bentzley 2021</a>). Some experts have proposed that deep brain stimulation (DBS) may be useful in the treatment of cocaine dependence (<a href="./references#CD007024-bbs2-0054" title="EskandariK , FattahiM , YazdanianH , HaghparastA . Is deep brain stimulation an effective treatment for psychostimulant dependency? A preclinical and clinical systematic review. Neurochemical Research2023;48(5):1255-68. [DOI: 10.1007/s11064-022-03818-3]">Eskandari 2022</a>). However, clinical experience is still scarce. </p> <p>Published evidence suggests that the effect of cocaine relates to its capacity to increase the availability of monoamines (dopamine, serotonin, and noradrenaline) in the brain. The dopamine increase in specific areas of the meso‐limbic system – which also occurs with drugs like heroin, alcohol, cannabis, and nicotine – mediates the rewarding effect of drugs and self‐administration behaviour in animals and humans (<a href="./references#CD007024-bbs2-0047" title="Di ChiaraG , ImperatoA . Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proceedings of the National Academy of Sciences of the United States of America1988;85(14):5274-8.">Di Chiara 1988</a>; <a href="./references#CD007024-bbs2-0048" title="DrevetsWC , PriceJC , KupferDJ , KinahanPE , LoprestiB , Holt D et al. PET measures of amphetamine-induced dopamine release in ventral versus dorsal striatum. Neuropsychopharmacology1999;21(6):694-709.">Drevets 1999</a>; <a href="./references#CD007024-bbs2-0049" title="DrevetsWC , GautierC , PriceJC , KupferDJ , KinahanPE , GraceAA , et al. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biological Psychiatry2001;49(2):81-96.">Drevets 2001</a>; <a href="./references#CD007024-bbs2-0102" title="VolkowND , FowlerJS , WangGJ . The addicted human brain: insights for imaging studies. Journal of Clinical Investigation2003;111(10):1444-51.">Volkow 2003</a>). </p> <p>Some compounds approved for the treatment of other pathologies may also prove useful for treating cocaine dependence (<a href="./references#CD007024-bbs2-0086" title="PretiA . New developments in the pharmacotherapy of cocaine abuse. Addiction Biology2007;12(2):133-51.">Preti 2007</a>; <a href="./references#CD007024-bbs2-0096" title="SofuogluM , KostenTR . Emerging pharmacological strategies in the fight against cocaine addiction. Expert Opinion on Emerging Drugs2006;11(1):91-8.">Sofuoglu 2006</a>; <a href="./references#CD007024-bbs2-0101" title="VocciFJ , ElkashefA . Pharmacotherapy and other treatments for cocaine abuse and dependence. Current Opinion in Psychiatry2005;18(3):265-70.">Vocci 2005</a>). In particular, preclinical and clinical observations support the use of disulfiram, a medication marketed for the treatment of alcohol use disorder (<a href="./references#CD007024-bbs2-0043" title="BuchholzJ , SaxonAJ . Medications to treat cocaine use disorders: current options. Current Opinion in Psychiatry2019;32(4):275-81. [PMID: 31008728]">Buchholz 2019</a>; <a href="./references#CD007024-bbs2-0068" title="KleczkowskaP , SulejczakD , ZarembaM . Advantages and disadvantages of disulfiram coadministered with popular addictive substances. European Journal of Pharmacology2021;904:174143. [DOI: 10.1016/j.ejphar.2021.174143]">Kleczkowska 2021</a>). </p> </section> <section id="CD007024-sec-0012"> <h3 class="title" id="CD007024-sec-0012">How the intervention might work</h3> <p>In people with alcohol use disorder, disulfiram works by inhibiting aldehyde dehydrogenase, an enzyme involved in the metabolism of alcohol. This induces an unpleasant reaction characterised by nausea, dizziness, and tachycardia (<a href="./references#CD007024-bbs2-0070" title="MacKillopJ , AgabioR , Feldstein EwingSW , HeiligM , KellyJF , LeggioL , Lingford-HughesA , PalmerAA , ParryCD , RayL , Rehm J Hazardous drinking and alcohol use disorders Nat Rev Dis Primers 2022 Dec 22, 8(1):80 doi: 101038/s41572-022-00406-1 PMID: 36550121, PMCID: PMC10284465. Hazardous drinking and alcohol use disorders. Nat Rev Dis Primers 2022 Dec 22;8(1):80. [DOI: 10.1038/s41572-022-00406-1] [PMID: 36550121]">MacKillop 2022</a>). Early studies suggested that an observed reduction in cocaine use in people treated with disulfiram for their alcohol use disorder was caused by the interruption of alcohol‐related disinhibition and impaired judgement (<a href="./references#CD007024-bbs2-0002" title="CarrollK , ZiedonisD , O'MalleyS , McCance-KatzE , GordonL , RounsavilleB . Pharmacological interventions for alcohol- and cocaine-abusing individuals: a pilot study of disulfiram vs. naltrexone. American Journal on Addictions1993;2:77-9. ">Carroll 1993</a>). However, more recent studies have indicated that disulfiram has a specific mechanism of action for treating cocaine dependence, different from the alcohol‐disulfiram reaction: because disulfiram is a generalised enzyme inhibitor, its effect on cocaine dependence could be ascribed to its ability to interfere with enzymes involved in the metabolism of cerebral monoamines. In particular, researchers have proposed that by inhibiting dopamine‐beta‐hydroxylase and thus producing an excess of dopamine and decreased synthesis of norepinephrine, disulfiram could improve the functioning of the meso‐limbic circuits disrupted by cocaine dependence (<a href="./references#CD007024-bbs2-0043" title="BuchholzJ , SaxonAJ . Medications to treat cocaine use disorders: current options. Current Opinion in Psychiatry2019;32(4):275-81. [PMID: 31008728]">Buchholz 2019</a>; <a href="./references#CD007024-bbs2-0068" title="KleczkowskaP , SulejczakD , ZarembaM . Advantages and disadvantages of disulfiram coadministered with popular addictive substances. European Journal of Pharmacology2021;904:174143. [DOI: 10.1016/j.ejphar.2021.174143]">Kleczkowska 2021</a>). </p> </section> <section id="CD007024-sec-0013"> <h3 class="title" id="CD007024-sec-0013">Why it is important to do this review</h3> <p>Despite decades of clinical trials evaluating the effects of antidepressants, anticonvulsants, psychostimulants, and dopaminergic medications on cocaine dependence, there are still no approved pharmacological treatments for this mental disorder. Several preclinical and clinical studies have investigated the potential efficacy of disulfiram for cocaine dependence, the neurobiological basis for its effect, and related safety issues. Several safety issues have been associated with disulfiram and disulfiram‐alcohol interactions (e.g. hepatic, psychiatric, and cardiovascular effects; <a href="./references#CD007024-bbs2-0071" title="MalcolmR , OliveMF , LechnerW . The safety of disulfiram for the treatment of alcohol and cocaine dependence in randomized clinical trials: guidance for clinical practice. Expert Opinion on Drug Safety2008;7(4):459-72. [DOI: 10.1517/14740338.7.4.459]">Malcolm 2008</a>). </p> <p>This is an update of a previous Cochrane review, which found low‐certainty evidence to support the clinical use of disulfiram for the treatment of cocaine dependence (<a href="./references#CD007024-bbs2-0104" title="PaniPP , TroguE , VaccaR , AmatoL , VecchiS , DavoliM . Disulfiram for the treatment of cocaine dependence. Cochrane Database of Systematic Reviews2010, Issue 1. Art. No: CD007024. [DOI: 10.1002/14651858.CD007024.pub2]">Pani 2010</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007024-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007024-sec-0014"></div> <p>To evaluate the efficacy and safety of disulfiram for the treatment of cocaine dependence.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007024-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007024-sec-0015"></div> <section id="CD007024-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007024-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) focused on the use of disulfiram for cocaine dependence. </p> </section> <section id="CD007024-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included trials in people with a diagnosis of cocaine dependence or cocaine use disorder, according to the <i>Diagnostic and Statistical Manual of Mental Disorders</i> (<a href="./references#CD007024-bbs2-0051" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition, Revised. Washington DC: American Psychiatric Association, 1987.">DSM‐III‐R</a>, <a href="./references#CD007024-bbs2-0052" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington DC: American Psychiatric Association, 1994.">DSM‐IV</a>, or <a href="./references#CD007024-bbs2-0050" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. American Psychiatric Association, 2013.">DSM‐5</a>). Trials that enroled people with additional diagnoses of substance dependence or with comorbid mental health conditions were also eligible. We excluded people aged under 18 years and pregnant women, as the clinical management of these populations is substantially different from that of the general adult population. </p> </section> <section id="CD007024-sec-0019"> <h4 class="title">Types of interventions</h4> <p>The experimental intervention was disulfiram alone or in combination with any psychosocial intervention. Eligible control interventions were placebo, no intervention, other pharmacological interventions, or any psychosocial intervention. </p> </section> <section id="CD007024-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD007024-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD007024-list-0001"> <li> <p>Efficacy</p> <ul id="CD007024-list-0002"> <li> <p>Frequency of cocaine use (mean number of days or weeks of cocaine use at the end of treatment) </p> </li> <li> <p>Amount of cocaine use (mean weight of cocaine used or money spent on cocaine at the end of treatment) </p> </li> <li> <p>Continuous abstinence from cocaine (number of participants who had achieved and maintained abstinence for at least three weeks at the end of treatment) </p> </li> <li> <p>Point abstinence from cocaine (number of participants who were abstinent at the end of treatment) </p> </li> </ul> </li> <li> <p>Acceptability</p> <ul id="CD007024-list-0003"> <li> <p>Dropout for any reason (number of participants who did not complete treatment)</p> </li> <li> <p>Dropout due to adverse events (number of participants who did not complete treatment due to adverse events) </p> </li> </ul> </li> <li> <p>Safety</p> <ul id="CD007024-list-0004"> <li> <p>Any adverse events (number of participants who experienced at least one adverse event)</p> </li> <li> <p>Serious adverse events (number of participants who experienced at least one serious adverse event) </p> </li> </ul> </li> </ul> </p> </section> <section id="CD007024-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD007024-list-0005"> <li> <p>Individual adverse events, measured subjectively or objectively (number of participants who experienced a specific adverse effect) </p> </li> <li> <p>Craving, as measured by validated scales such as the Brief Substance Craving Scale (BSCS) or a visual analogue scale (VAS) </p> </li> <li> <p>Severity of dependence, as measured by validated scales such as the Addiction Severity Index (ASI), the Clinical Global Impression (CGI) scale (self‐report and observer versions), or the Severity of Dependence Scale (SDS) </p> </li> <li> <p>Psychiatric symptoms/psychological distress, diagnosed using standard instruments such as the Diagnostic and Statistical Manual of Mental Disorders (DSM), or measured by validated scales such as the Hamilton Depression Rating Scale (HDRS), the Profile of Mood States Scale (POMSS), or the Positive and Negative Syndrome Scale (PANSS) </p> </li> </ul> </p> </section> </section> </section> <section id="CD007024-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD007024-sec-0024"> <h4 class="title">Electronic searches</h4> <p>For this update, we revised all our search strategies in line with current Cochrane Drugs and Alcohol Group practices. We searched the following databases up to 25 August 2022. </p> <p> <ul id="CD007024-list-0006"> <li> <p>Cochrane Drugs and Alcohol Group (CDAG) Specialised Register (searched 25 August 2022; <a href="./appendices#CD007024-sec-0115">Appendix 1</a>) </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2022, issue 8) via <a href="https://onlinelibrary.wiley.com/" target="_blank">onlinelibrary.wiley.com</a> (<a href="./appendices#CD007024-sec-0116">Appendix 2</a>) </p> </li> <li> <p>MEDLINE via Ovid (January 2009 to 25 August 2022; <a href="./appendices#CD007024-sec-0117">Appendix 3</a>) </p> </li> <li> <p>Embase via Ovid (January 2009 to 25 August 2022; <a href="./appendices#CD007024-sec-0118">Appendix 4</a>) </p> </li> <li> <p>PsycINFO via Ovid (January 2009 to 25 August 2022; <a href="./appendices#CD007024-sec-0119">Appendix 5</a>) </p> </li> <li> <p>CINAHL (EBSCOhost; January 2009 to 25 August 2022; <a href="./appendices#CD007024-sec-0120">Appendix 6</a>) </p> </li> </ul> </p> <p>We also searched the following trials registries.</p> <p> <ul id="CD007024-list-0007"> <li> <p>U.S. National Institutes of Health Ongoing Trials Registry ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>; searched 25 August 2022) </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP; <a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>; searched 25 August 2022) </p> </li> </ul> </p> </section> <section id="CD007024-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We also searched the reference lists of all relevant papers and conference proceedings likely to contain trials relevant to the review. We contacted investigators to ask about unpublished or incomplete trials. </p> <p>We conducted all searches without language restrictions.</p> </section> </section> <section id="CD007024-sec-0026"> <h3 class="title" id="CD007024-sec-0026">Data collection and analysis</h3> <section id="CD007024-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (FT, RA) screened the titles and abstracts of the records retrieved by the search and eliminated those that they considered were clearly ineligible. We obtained the full‐text articles of all potentially eligible records, and the same two review authors independently assessed each article against our inclusion criteria. We resolved any disagreements by discussion among all review authors. </p> </section> <section id="CD007024-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Three review authors (FT, RA, PP) independently extracted the following data from the included studies. </p> <p> <ul id="CD007024-list-0008"> <li> <p>Number and characteristics of participants</p> </li> <li> <p>Setting and country of the study</p> </li> <li> <p>Details of experimental and control interventions (e.g. dose, duration)</p> </li> <li> <p>Length of follow‐up</p> </li> <li> <p>Types of outcomes</p> </li> <li> <p>Funding and conflicts of interest</p> </li> </ul> </p> <p>We extracted relevant data reported in graphs using WebPlotDigitizer software (<a href="./references#CD007024-bbs2-0090" title="WebPlotDigitizer: version 4.6 (automeris.io/WebPlotDigitizer). RohatgiA . Pacifica, California, USA: Ankit Rohatgi, September, 2022.">Rohatgi 2022</a>). We resolved any disagreements by discussion. </p> </section> <section id="CD007024-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (SM, FT) independently assessed the risk of bias of the included studies using the original Cochrane risk of bias tool (RoB 1), which covers the following domains (<a href="./references#CD007024-bbs2-0065" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). </p> <p> <ul id="CD007024-list-0009"> <li> <p>Random sequence generation (selection bias)</p> </li> <li> <p>Allocation concealment (selection bias)</p> </li> <li> <p>Blinding of participants and personnel (performance bias)</p> </li> <li> <p>Blinding of outcome assessment (detection bias)</p> </li> <li> <p>Incomplete outcome data (attrition bias)</p> </li> <li> <p>Selective outcome reporting (reporting bias)</p> </li> <li> <p>Other sources of bias (other bias)</p> </li> </ul> </p> <p>See <a href="./appendices#CD007024-sec-0121">Appendix 7</a> for a detailed description of the criteria for assessing risk of bias. </p> <p>We did not assess other potential sources of bias as we judged that there were no other relevant threats to validity to be searched for in the types of studies we aimed to include in the review. </p> <p>We assessed performance bias and detection bias separately for objective outcomes (e.g. point abstinence) and subjective outcomes (e.g. craving). </p> </section> <section id="CD007024-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes, we calculated risk ratios (RRs) with 95% confidence intervals (CIs). For continuous outcomes, we calculated the mean difference (MD) with 95% CI when the studies used the same instrument for assessing the outcome, or the standardised mean difference (SMD) when the studies used different instruments. </p> <p>We decided not to use data presented as number of urine tests (positive or negative) over the total number of tests in the experimental and control group as a measure of substance use, because using tests instead of participants as the unit of analysis violates the hypothesis of independence among observations. </p> </section> <section id="CD007024-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>If two or more comparisons in a multiarm trial were eligible for inclusion in the same meta‐analysis, and these comparisons had one or more arms in common (e.g. dose A versus placebo and dose B versus placebo), we split the events and participants of the shared arm between the comparisons. This method avoids the multiple use of participants in the pooled estimate of treatment effect while retaining information from each arm of the trial, though it compromises the precision of the pooled estimate. </p> </section> <section id="CD007024-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>If studies did not report the standard deviation (SD), we used the mean of the available SDs from the other included studies. The risk of bias assessment covered missing information related to method of randomisation, non‐reporting of outcomes, dropouts, loss to follow‐up, or missing measurements for some outcomes. </p> </section> <section id="CD007024-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We analysed statistical heterogeneity using the I² statistic and the Chi² test (<a href="./references#CD007024-bbs2-0063" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta analyses. BMJ2003;327:557-60.">Higgins 2003</a>). We regarded heterogeneity as substantial if the I² statistic was greater than 50% or if the P value of the Chi² test was below 0.10 (<a href="./references#CD007024-bbs2-0046" title="DeeksJJ , HigginsJP , Altman DG (editors) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0. Cochrane, 2017.">Deeks 2017</a>). Following guidance in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, we used the following rough guide to interpret the I<sup>2</sup> values (<a href="./references#CD007024-bbs2-0046" title="DeeksJJ , HigginsJP , Altman DG (editors) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0. Cochrane, 2017.">Deeks 2017</a>). </p> <p> <ul id="CD007024-list-0010"> <li> <p>0% to 40%: might not be important</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity</p> </li> <li> <p>75% to 100%: considerable heterogeneity</p> </li> </ul> </p> </section> <section id="CD007024-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>If we included at least 10 datasets in a meta‐analysis, we created a funnel plot (plot of the effect estimate from each study against the sample size or effect standard error) to assess publication bias. </p> </section> <section id="CD007024-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We combined the outcomes of the individual trials through meta‐analysis where possible (when the interventions and outcomes of the different trials were comparable) using a random‐effects model, because we expected a certain degree of heterogeneity between trials. If we identified considerable statistical heterogeneity (i.e. I² value of 75% or greater) or clinical heterogeneity, we considered not pooling the data. </p> </section> <section id="CD007024-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Where a meta‐analysis of a primary outcome included 10 or more datasets, we performed a subgroup analysis to investigate sources of heterogeneity and assess differences in treatment efficacy and safety according to the presence of comorbid mental disorders (all participants versus some participants versus no participants). Based on the evidence from the trials, we decided to perform subgroup analysis according to the presence of comorbid alcohol dependence and comorbid opioid dependence. </p> </section> <section id="CD007024-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>To incorporate our assessment of risk of bias in the review process, we first plotted the intervention effect estimates stratified by risk of bias for allocation concealment (selection bias). If studies with different risk of selection bias showed different effect estimates, we planned to perform sensitivity analysis by excluding studies at high risk of selection bias from the analysis. </p> </section> <section id="CD007024-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We created a summary of findings table for each comparison using GRADEpro software to present the findings for our primary outcomes (<a href="./references#CD007024-bbs2-0059" title="Hamilton (ON). GRADEproGDT . McMaster University (developed by Evidence Prime), 2015.">GRADEpro 2015</a>). Two review authors (SM and SV) assessed the certainty of the evidence using the GRADE approach. With GRADE, evidence from RCTs starts at high certainty but can be downgraded for limitations related to risk of bias, consistency of effect, imprecision, indirectness, and publication bias (<a href="./references#CD007024-bbs2-0040" title="AtkinsD , BestD , BrissPA , EcclesM , Falck-YtterY , FlottorpS , et al. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328(7454):1490.">Atkins 2004</a>). We used the methods and recommendations described in Chapter 14 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007024-bbs2-0066" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. training.cochrane.org/handbook/archive/v6.3.">Higgins 2022</a>). We justified all decisions to downgrade or upgrade the certainty of evidence using footnotes. The final GRADE rating falls into one of the following four categories. </p> <p> <ul id="CD007024-list-0011"> <li> <p>High certainty: we are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p>Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> </li> <li> <p>Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p>Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007024-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007024-sec-0039"></div> <section id="CD007024-sec-0040"> <h3 class="title">Description of studies</h3> <p>For a detailed descriptions of all studies, see the <a href="./references#CD007024-sec-0131" title="">Characteristics of included studies</a>, <a href="./references#CD007024-sec-0132" title="">Characteristics of excluded studies</a>, and <a href="./references#CD007024-sec-0133" title="">Characteristics of ongoing studies</a> tables. </p> <section id="CD007024-sec-0041"> <h4 class="title">Results of the search</h4> <p><a href="#CD007024-fig-0001">Figure 1</a> shows the study selection process in a PRISMA flow diagram. </p> <div class="figure" id="CD007024-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA flow diagram illustrating the study selection process." data-id="CD007024-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA flow diagram illustrating the study selection process.</p> </div> </div> </div> <p>For this update, we identified 288 records through database searching. After removing duplicates, we were left with 166 unique references. We excluded 130 references on the basis of their title and abstract, and we retrieved the full‐text articles of the remaining 36 references for more detailed evaluation. Thirteen articles were ineligible (see <a href="./references#CD007024-sec-0132" title="">Characteristics of excluded studies</a> table), three articles were from ongoing studies (see <a href="./references#CD007024-sec-0133" title="">Characteristics of ongoing studies</a> table), seven articles were already included in the previous version of the review, and 13 articles were from six new eligible RCTs (see <a href="./references#CD007024-sec-0131" title="">Characteristics of included studies</a> table). </p> <p>In this update, we included 13 RCTs involving a total of 1191 participants, compared to seven RCTs with 492 participants in the previous version (<a href="./references#CD007024-bbs2-0104" title="PaniPP , TroguE , VaccaR , AmatoL , VecchiS , DavoliM . Disulfiram for the treatment of cocaine dependence. Cochrane Database of Systematic Reviews2010, Issue 1. Art. No: CD007024. [DOI: 10.1002/14651858.CD007024.pub2]">Pani 2010</a>). Among the secondary references of new included studies are four articles previously listed as ongoing studies (<a href="./references#CD007024-bbs2-0079" title="NCT00149630. Pharmacogenetics of disulfiram forcocaine (disulfiram) [Effectiveness of disulfiram for treating cocaine dependence in individuals with different dopamine beta hydroxylase (DBH) genes]. clinicaltrials.gov/study/NCT00149630 (first received 6 September 2005).">NCT00149630</a>; <a href="./references#CD007024-bbs2-0080" title="NCT00218608. Disulfiram for treating cocaine dependence in individuals maintained on methadone [Disulfiram for cocaine abuse in methadone – patients]. classic.clinicaltrials.gov/ct2/show/NCT00218608 (first received 22 September 2005).">NCT00218608</a>; <a href="./references#CD007024-bbs2-0081" title="NCT00350649. Maximizing the efficacy of cognitive behavior therapy and contingency management. clinicaltrials.gov/show/NCT00350649 (first received 11 July 2006).">NCT00350649</a>; <a href="./references#CD007024-bbs2-0082" title="NCT00395850. Disulfiram for cocaine abuse. clinicaltrials.gov/study/NCT00395850 (first received 2 November 2006).">NCT00395850</a>), and one study previously listed as awaiting classification (<a href="./references#CD007024-bbs2-0093" title="SchottenfeldRS , ChawarskiMC , GeorgeTP , CubellsJF . Pharmacogenetics of disulfiram for cocaine treatment: role of DBH genotype. Sixty-Sixth Annual Scientific Meeting of the College on Problems of Drug Dependence June 12-17, 2004.">Schottenfeld 2004</a>). </p> </section> <section id="CD007024-sec-0042"> <h4 class="title">Included studies</h4> <p>We extracted a single dataset from six RCTs (<a href="./references#CD007024-bbs2-0001" title="ACTRN12611000103965. Disulfiram for the treatment of crack dependence. A pilot study. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000103965 (first received 31 January 2012). BaldaçaraL , DinizTA , ParreiraBL , MilhomemJJ , AlmeidaLJ , FernandesCC . Could disulfiram be a new treatment for crack cocaine dependence? A pilot study. Brazilian Journal of Psychiatry2013;35:97-8. ">Baldacara 2013</a>; <a href="./references#CD007024-bbs2-0002" title="CarrollK , ZiedonisD , O'MalleyS , McCance-KatzE , GordonL , RounsavilleB . Pharmacological interventions for alcohol- and cocaine-abusing individuals: a pilot study of disulfiram vs. naltrexone. American Journal on Addictions1993;2:77-9. ">Carroll 1993</a>; <a href="./references#CD007024-bbs2-0011" title="GeorgeTP , ChawarskiMC , PakesJ , CarrollKM , KostenTDR , SchottenfeldRS . Disulfiram versus placebo for cocaine dependence in Buprenorhine-mantained subjects: a preliminary trial. Biological Psychiatry2000;47:1080-6. ">George 2000</a>; <a href="./references#CD007024-bbs2-0014" title="KampangkaewJP , SpellicyCJ , NielsenEM , HardingMJ , YeA , HamonSC , et al. Pharmacogenetic role of dopamine transporter (SLC6A3) variation on response to disulfiram treatment for cocaine addiction. American Journal on Addictions 2019 Jul;28(4):311-7. KostenTR , WuG , HuangW , HardingMJ , HamonSC , LappalainenJ , et al. Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine beta-hydroxylase. Biological Psychiatry2013;73(3):219-24. NCT00000278. Disulfiram for cocaine-alcohol abuse - 3. clinicaltrials.gov/show/NCT00000278 (first received 21 September 1999). NCT00149630. Pharmacogenetics of disulfiram for cocaine. clinicaltrials.gov/show/NCT00149630 (first received 8 September 2005). NCT00729300. A study of the relationship between disulfiram and cocaine self-administration. clinicaltrials.gov/show/NCT00729300 (first received 7 August 2008). NielsenD , HuangW , HardingM , HamonS , LindsayJ , KostenT . Interaction of specific genetic variants with treatment effectiveness in disulfiram pharmacotherapy for cocaine dependence. In: Neuropsychopharmacology. Vol. 35. 2010:S341. NielsenDA , HardingMJ , HamonSC , HuangW , KostenTR . Modifying the role of serotonergic 5-HTTLPR and TPH2 variants on disulfiram treatment of cocaine addiction: a preliminary study. Genes, Brain and Behavior2012;11(8):1001-8. ShorterD , NielsenDA , HuangW , HardingMJ , HamonSC , KostenTR . Pharmacogenetic randomized trial for cocaine abuse: disulfiram and a1-adrenoceptor gene variation. European Neuropsychopharmacology2013;23(11):1401-7. SpellicyCJ , KostenTR , HamonSC , HardingMJ , NielsenDA . ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse. Pharmacogenetics and Genomics2013;23(7):333-40. SpellicyCJ , KostenTR , HamonSC , HardingMJ , NielsenDA . The MTHFR C677T variant is associated with responsiveness to disulfiram treatment for cocaine dependency. Frontiers in Psychiatry2013;3:109. [DOI: 10.3389/fpsyt.2012.00109]Thomas PS Jr, NielsenEM , SpellicyCJ , HardingMJ , YeA , PatriquinM , et al. The OPRD1 rs678849 variant influences outcome of disulfiram treatment for cocaine dependency in methadone-maintained patients. Psychiatric Genetics2021;31(3):88-94. ">Kosten 2013</a>; <a href="./references#CD007024-bbs2-0018" title="PetrakisIL , CarrollKM , NichC , GordonLT , McCance-KatzEF , FrankforteT , et al. Disulfiram treatment for cocaine dependence in Methadone maintained opioid addicts. Addiction2000;95(2):219-28. ">Petrakis 2000</a>; <a href="./references#CD007024-bbs2-0021" title="NCT00913484. Disulfiram for cocaine abuse in buprenorphine treatment. clinicaltrials.gov/show/ NCT00913484 (first received 4 June 2009). SchottenfeldRS , ChawarskiMC , CubellsJF , GeorgeTP , LappalainenJ , KostenTR . Randomized clinical trial of disulfiram for cocaine dependence or abuse during buprenorphine treatment. Drug and Alcohol Dependence2013;136:36-42. ">Schottenfeld 2013</a>), two datasets from each of six RCTs (<a href="./references#CD007024-bbs2-0003" title="CarrollKM , BallSA , McCanceE , RounsavilleB . Treatment for cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction1998;93(5):713-28. ">Carroll 1998 dataset a</a>; <a href="./references#CD007024-bbs2-0004" title="CarrollKM , BallSA , McCanceE , RounsavilleB . Treatment for cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction1998;93(5):713-28. ">Carroll 1998 dataset b</a>; <a href="./references#CD007024-bbs2-0005" title="CarrollKM , FentonLR , BallSA , NichCN , FrankforterTL , ShiJ , et al. Efficacy of Disulfiram and cognitive behavioral therapy in cocaine-dependent outpatients. Archives of General Psychiatry2004;61:264-72. ">Carroll 2004 dataset a</a>; <a href="./references#CD007024-bbs2-0006" title="CarrollKM , FentonLR , BallSA , NichCN , FrankforterTL , ShiJ , et al. Efficacy of Disulfiram and cognitive behavioral therapy in cocaine-dependent outpatients. Archives of General Psychiatry2004;61:264-72. ">Carroll 2004 dataset b</a>; <a href="./references#CD007024-bbs2-0007" title="CarrollKM , NichC , ShiJM , EaganD , BallSA . Efficacy of disulfiram and Twelve Step Facilitation in cocaine-dependent individuals maintained on methadone: a randomized placebo-controlled trial. Drug and Alcohol Dependence2012;126:224-31. ">Carroll 2012 dataset a</a>; <a href="./references#CD007024-bbs2-0008" title="CarrollKM , NichC , ShiJM , EaganD , BallSA . Efficacy of disulfiram and Twelve Step Facilitation in cocaine-dependent individuals maintained on methadone: a randomized placebo-controlled trial. Drug and Alcohol Dependence2012;126:224-31. ">Carroll 2012 dataset b</a>; <a href="./references#CD007024-bbs2-0009" title="CarrollKM , NichC , PetryNM , EaganDA , ShiJM , &amp; BallSA . A randomized factorial trial of disulfiram and contingency management to enhance cognitive behavioral therapy for cocaine dependence. Drug and Alcohol Dependence2016;160:135-42. De VitoEE , DongG , KoberH , XuJ , CarrollK , PotenzaMN . Neural effects of treatment in a trial of behavioral therapies and disulfiram for cocaine dependence. In: Drug and Alcohol Dependence. Vol. 171. 2017:e54. DeVitoEE , DongG , KoberH , XuJ , CarrollKM , PotenzaMN . Functional neural changes following behavioral therapies and disulfiram for cocaine dependence. Psychology of Addictive Behaviors2017;31:534. NCT00350870. CBT with disulfiram and contingency management. clinicaltrials.gov/show/NCT00350870 (first received 11 July 2006). ">Carroll 2016 dataset a</a>; <a href="./references#CD007024-bbs2-0010" title="CarrollKM , NichC , PetryNM , EaganDA , ShiJM , BallSA . A randomized factorial trial of disulfiram and contingency management to enhance cognitive behavioral therapy for cocaine dependence. Drug and Alcohol Dependence2016;160:135-42. DeVitoEE , DongG , KoberH , XuJ , CarrollKM , PotenzaMN . Functional neural changes following behavioral therapies and disulfiram for cocaine dependence. Psychology of Addictive Behavior2017;31:534. ">Carroll 2016 dataset b</a>; <a href="./references#CD007024-bbs2-0012" title="GrassiMC , CioceAM , GiudiciFD , AntonilliL , NenciniP . Short-term efficacy of disulfiram or naltrexone in reducing positive urinalysis for both cocaine and cocaethylene in cocaine abusers: a pilot study. Pharmacological Research2007;55(2):117-21. ">Grassi 2007 dataset a</a>; <a href="./references#CD007024-bbs2-0013" title="GrassiMC , CioceAM , GiudiciFD , AntonilliL , NenciniP . Short-term efficacy of disulfiram or naltrexone in reducing positive urinalysis for both cocaine and cocaethylene in cocaine abusers: a pilot study. Pharmacological Research2007;55(2):117-21. ">Grassi 2007 dataset b</a>; <a href="./references#CD007024-bbs2-0019" title="NCT00142844. Combination of disulfiram plus naltrexone to treat both cocaine- and alcohol-dependent individuals - 1 [Two medications, disulfiram and naltrexone, in the treatment of patients with both cocaine and alcohol dependence]. clinicaltrials.gov/show/NCT00142844 (first received 2 September 2005). [Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1 - Full Text View - ClinicalTrials.gov]PettinatiHM , KampmanKM , LynchKG , XieH , DackisC , RabinowitzAR , et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addictive Behaviors2008;33(5):651-67. ">Pettinati 2008 dataset a</a>; <a href="./references#CD007024-bbs2-0020" title="PettinatiHM , KampmanKM , LynchKG , XieH , DackisC , RabinowitzAR , et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addictive Behaviors2008;33(5):651-67. ">Pettinati 2008 dataset b</a>), and three datasets from one RCT (<a href="./references#CD007024-bbs2-0015" title="AtkinsonTS , SandersN , MancinoM , OlivetoA . Effects of disulfiram on QTc interval in non-opioid-dependent and methadone-treated cocaine-dependent patients. Journal of Addiction Medicine2013;7(4):243-8. [DOI: 10.1097/ADM.0b013e3182928e02]NCT00395850. Disulfiram for cocaine abuse. clinicaltrials.gov/show/NCT00395850 (first received 2 November 2006). NCT00580827. Clinical efficacy of disulfiram in LAAM-maintained cocaine abusers. clinicaltrials.gov/show/ NCT00580827 (first received 27 December 2007). OlivetoA , PolingJ , MancinoMJ , FeldmanZ , CubellsJF , PruzinskyR , et al. Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drugs and Alcohol Dependence2011;113(2-3):184-91. ">Oliveto 2011 dataset a</a>; <a href="./references#CD007024-bbs2-0016" title="NCT00395850. Disulfiram for Cocaine Abuse. clinicaltrials.gov/show/ NCT00395850 (first received 2 November 2006). [ClinicalTrials.gov Identifier: NCT00395850.]OlivetoA , PolingJ , MancinoMJ , FeldmanZ , CubellsJF , PruzinskyR , et al. Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drugs and Alcohol Dependence2011;113(2-3):184-91. ">Oliveto 2011 dataset b</a>; <a href="./references#CD007024-bbs2-0017" title="NCT00395850. Disulfiram for cocaine abuse. clinicaltrials.gov/show/ NCT00395850;(first received 2 November 2006). OlivetoA , PolingJ , MancinoMJ , FeldmanZ , CubellsJF , PruzinskyR , et al. Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drugs and Alcohol Dependence2011;113(2-3):184-91. ">Oliveto 2011 dataset c</a>), for a total of 21 datasets. We created a study ID for each dataset, though this is not standard Cochrane practice. </p> <section id="CD007024-sec-0043"> <h5 class="title">Participants</h5> <p>The 13 RCTs included a total of 1191 participants with cocaine dependence or cocaine use disorder according to DSM criteria (<a href="./references#CD007024-bbs2-0051" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition, Revised. Washington DC: American Psychiatric Association, 1987.">DSM‐III‐R</a>; <a href="./references#CD007024-bbs2-0052" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington DC: American Psychiatric Association, 1994.">DSM‐IV</a>). The proportion of male participants ranged from 48% to 100%; the mean age ranged from 28.6 years to 41.6 years. </p> <p>Five RCTs enroled people with comorbid alcohol abuse or dependence (<a href="./references#CD007024-bbs2-0002" title="CarrollK , ZiedonisD , O'MalleyS , McCance-KatzE , GordonL , RounsavilleB . Pharmacological interventions for alcohol- and cocaine-abusing individuals: a pilot study of disulfiram vs. naltrexone. American Journal on Addictions1993;2:77-9. ">Carroll 1993</a>; <a href="./references#CD007024-bbs2-0003" title="CarrollKM , BallSA , McCanceE , RounsavilleB . Treatment for cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction1998;93(5):713-28. ">Carroll 1998 dataset a</a>; <a href="./references#CD007024-bbs2-0004" title="CarrollKM , BallSA , McCanceE , RounsavilleB . Treatment for cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction1998;93(5):713-28. ">Carroll 1998 dataset b</a>; <a href="./references#CD007024-bbs2-0005" title="CarrollKM , FentonLR , BallSA , NichCN , FrankforterTL , ShiJ , et al. Efficacy of Disulfiram and cognitive behavioral therapy in cocaine-dependent outpatients. Archives of General Psychiatry2004;61:264-72. ">Carroll 2004 dataset a</a>; <a href="./references#CD007024-bbs2-0006" title="CarrollKM , FentonLR , BallSA , NichCN , FrankforterTL , ShiJ , et al. Efficacy of Disulfiram and cognitive behavioral therapy in cocaine-dependent outpatients. Archives of General Psychiatry2004;61:264-72. ">Carroll 2004 dataset b</a>; <a href="./references#CD007024-bbs2-0060" title="GrassiMC , CioceAM , GiudiciFD , AntonilliL , NenciniP . Short-term efficacy of disulfiram or naltrexone in reducing positive urinalysis for both cocaine and cocaethylene in cocaine abusers: a pilot study. Pharmacological Research2007;55(2):117-21.">Grassi 2007</a>; <a href="./references#CD007024-bbs2-0019" title="NCT00142844. Combination of disulfiram plus naltrexone to treat both cocaine- and alcohol-dependent individuals - 1 [Two medications, disulfiram and naltrexone, in the treatment of patients with both cocaine and alcohol dependence]. clinicaltrials.gov/show/NCT00142844 (first received 2 September 2005). [Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1 - Full Text View - ClinicalTrials.gov]PettinatiHM , KampmanKM , LynchKG , XieH , DackisC , RabinowitzAR , et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addictive Behaviors2008;33(5):651-67. ">Pettinati 2008 dataset a</a>; <a href="./references#CD007024-bbs2-0020" title="PettinatiHM , KampmanKM , LynchKG , XieH , DackisC , RabinowitzAR , et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addictive Behaviors2008;33(5):651-67. ">Pettinati 2008 dataset b</a>); six RCTs recruited people with comorbid opioid dependence or opioid use disorder in treatment with methadone (<a href="./references#CD007024-bbs2-0007" title="CarrollKM , NichC , ShiJM , EaganD , BallSA . Efficacy of disulfiram and Twelve Step Facilitation in cocaine-dependent individuals maintained on methadone: a randomized placebo-controlled trial. Drug and Alcohol Dependence2012;126:224-31. ">Carroll 2012 dataset a</a>; <a href="./references#CD007024-bbs2-0008" title="CarrollKM , NichC , ShiJM , EaganD , BallSA . Efficacy of disulfiram and Twelve Step Facilitation in cocaine-dependent individuals maintained on methadone: a randomized placebo-controlled trial. Drug and Alcohol Dependence2012;126:224-31. ">Carroll 2012 dataset b</a>; <a href="./references#CD007024-bbs2-0014" title="KampangkaewJP , SpellicyCJ , NielsenEM , HardingMJ , YeA , HamonSC , et al. Pharmacogenetic role of dopamine transporter (SLC6A3) variation on response to disulfiram treatment for cocaine addiction. American Journal on Addictions 2019 Jul;28(4):311-7. KostenTR , WuG , HuangW , HardingMJ , HamonSC , LappalainenJ , et al. Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine beta-hydroxylase. Biological Psychiatry2013;73(3):219-24. NCT00000278. Disulfiram for cocaine-alcohol abuse - 3. clinicaltrials.gov/show/NCT00000278 (first received 21 September 1999). NCT00149630. Pharmacogenetics of disulfiram for cocaine. clinicaltrials.gov/show/NCT00149630 (first received 8 September 2005). NCT00729300. A study of the relationship between disulfiram and cocaine self-administration. clinicaltrials.gov/show/NCT00729300 (first received 7 August 2008). NielsenD , HuangW , HardingM , HamonS , LindsayJ , KostenT . Interaction of specific genetic variants with treatment effectiveness in disulfiram pharmacotherapy for cocaine dependence. In: Neuropsychopharmacology. Vol. 35. 2010:S341. NielsenDA , HardingMJ , HamonSC , HuangW , KostenTR . Modifying the role of serotonergic 5-HTTLPR and TPH2 variants on disulfiram treatment of cocaine addiction: a preliminary study. Genes, Brain and Behavior2012;11(8):1001-8. ShorterD , NielsenDA , HuangW , HardingMJ , HamonSC , KostenTR . Pharmacogenetic randomized trial for cocaine abuse: disulfiram and a1-adrenoceptor gene variation. European Neuropsychopharmacology2013;23(11):1401-7. SpellicyCJ , KostenTR , HamonSC , HardingMJ , NielsenDA . ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse. Pharmacogenetics and Genomics2013;23(7):333-40. SpellicyCJ , KostenTR , HamonSC , HardingMJ , NielsenDA . The MTHFR C677T variant is associated with responsiveness to disulfiram treatment for cocaine dependency. Frontiers in Psychiatry2013;3:109. [DOI: 10.3389/fpsyt.2012.00109]Thomas PS Jr, NielsenEM , SpellicyCJ , HardingMJ , YeA , PatriquinM , et al. The OPRD1 rs678849 variant influences outcome of disulfiram treatment for cocaine dependency in methadone-maintained patients. Psychiatric Genetics2021;31(3):88-94. ">Kosten 2013</a>; <a href="./references#CD007024-bbs2-0015" title="AtkinsonTS , SandersN , MancinoM , OlivetoA . Effects of disulfiram on QTc interval in non-opioid-dependent and methadone-treated cocaine-dependent patients. Journal of Addiction Medicine2013;7(4):243-8. [DOI: 10.1097/ADM.0b013e3182928e02]NCT00395850. Disulfiram for cocaine abuse. clinicaltrials.gov/show/NCT00395850 (first received 2 November 2006). NCT00580827. Clinical efficacy of disulfiram in LAAM-maintained cocaine abusers. clinicaltrials.gov/show/ NCT00580827 (first received 27 December 2007). OlivetoA , PolingJ , MancinoMJ , FeldmanZ , CubellsJF , PruzinskyR , et al. Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drugs and Alcohol Dependence2011;113(2-3):184-91. ">Oliveto 2011 dataset a</a>; <a href="./references#CD007024-bbs2-0016" title="NCT00395850. Disulfiram for Cocaine Abuse. clinicaltrials.gov/show/ NCT00395850 (first received 2 November 2006). [ClinicalTrials.gov Identifier: NCT00395850.]OlivetoA , PolingJ , MancinoMJ , FeldmanZ , CubellsJF , PruzinskyR , et al. Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drugs and Alcohol Dependence2011;113(2-3):184-91. ">Oliveto 2011 dataset b</a>; <a href="./references#CD007024-bbs2-0017" title="NCT00395850. Disulfiram for cocaine abuse. clinicaltrials.gov/show/ NCT00395850;(first received 2 November 2006). OlivetoA , PolingJ , MancinoMJ , FeldmanZ , CubellsJF , PruzinskyR , et al. Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drugs and Alcohol Dependence2011;113(2-3):184-91. ">Oliveto 2011 dataset c</a>; <a href="./references#CD007024-bbs2-0018" title="PetrakisIL , CarrollKM , NichC , GordonLT , McCance-KatzEF , FrankforteT , et al. Disulfiram treatment for cocaine dependence in Methadone maintained opioid addicts. Addiction2000;95(2):219-28. ">Petrakis 2000</a>) or buprenorphine (<a href="./references#CD007024-bbs2-0058" title="GeorgeTP , ChawarskiMC , PakesJ , CarrollKM , KostenTR , SchottenfeldRS . Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial. Biological Psychiatry2000;47(12):1080-6.">George 2000</a>; <a href="./references#CD007024-bbs2-0021" title="NCT00913484. Disulfiram for cocaine abuse in buprenorphine treatment. clinicaltrials.gov/show/ NCT00913484 (first received 4 June 2009). SchottenfeldRS , ChawarskiMC , CubellsJF , GeorgeTP , LappalainenJ , KostenTR . Randomized clinical trial of disulfiram for cocaine dependence or abuse during buprenorphine treatment. Drug and Alcohol Dependence2013;136:36-42. ">Schottenfeld 2013</a>). </p> </section> <section id="CD007024-sec-0044"> <h5 class="title">Treatment regimens and setting</h5> <p>The disulfiram dose ranged from 62.5 mg/day (<a href="./references#CD007024-bbs2-0015" title="AtkinsonTS , SandersN , MancinoM , OlivetoA . Effects of disulfiram on QTc interval in non-opioid-dependent and methadone-treated cocaine-dependent patients. Journal of Addiction Medicine2013;7(4):243-8. [DOI: 10.1097/ADM.0b013e3182928e02]NCT00395850. Disulfiram for cocaine abuse. clinicaltrials.gov/show/NCT00395850 (first received 2 November 2006). NCT00580827. Clinical efficacy of disulfiram in LAAM-maintained cocaine abusers. clinicaltrials.gov/show/ NCT00580827 (first received 27 December 2007). OlivetoA , PolingJ , MancinoMJ , FeldmanZ , CubellsJF , PruzinskyR , et al. Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drugs and Alcohol Dependence2011;113(2-3):184-91. ">Oliveto 2011 dataset a</a>) to 400 mg/day (<a href="./references#CD007024-bbs2-0012" title="GrassiMC , CioceAM , GiudiciFD , AntonilliL , NenciniP . Short-term efficacy of disulfiram or naltrexone in reducing positive urinalysis for both cocaine and cocaethylene in cocaine abusers: a pilot study. Pharmacological Research2007;55(2):117-21. ">Grassi 2007 dataset a</a>; <a href="./references#CD007024-bbs2-0013" title="GrassiMC , CioceAM , GiudiciFD , AntonilliL , NenciniP . Short-term efficacy of disulfiram or naltrexone in reducing positive urinalysis for both cocaine and cocaethylene in cocaine abusers: a pilot study. Pharmacological Research2007;55(2):117-21. ">Grassi 2007 dataset b</a>). Most studies used 250 mg/day, and the median dose was 250.5 mg/day. </p> <p>In all RCTs, participants received psychosocial treatments in addition to disulfiram, though two multiarm studies included experimental and control arms with no psychosocial treatment (<a href="./references#CD007024-bbs2-0008" title="CarrollKM , NichC , ShiJM , EaganD , BallSA . Efficacy of disulfiram and Twelve Step Facilitation in cocaine-dependent individuals maintained on methadone: a randomized placebo-controlled trial. Drug and Alcohol Dependence2012;126:224-31. ">Carroll 2012 dataset b</a>; <a href="./references#CD007024-bbs2-0010" title="CarrollKM , NichC , PetryNM , EaganDA , ShiJM , BallSA . A randomized factorial trial of disulfiram and contingency management to enhance cognitive behavioral therapy for cocaine dependence. Drug and Alcohol Dependence2016;160:135-42. DeVitoEE , DongG , KoberH , XuJ , CarrollKM , PotenzaMN . Functional neural changes following behavioral therapies and disulfiram for cocaine dependence. Psychology of Addictive Behavior2017;31:534. ">Carroll 2016 dataset b</a>). All RCTs except <a href="./references#CD007024-bbs2-0002" title="CarrollK , ZiedonisD , O'MalleyS , McCance-KatzE , GordonL , RounsavilleB . Pharmacological interventions for alcohol- and cocaine-abusing individuals: a pilot study of disulfiram vs. naltrexone. American Journal on Addictions1993;2:77-9. ">Carroll 1993</a> clearly defined the psychosocial treatment concomitantly given with disulfiram, as follows. </p> <p> <ul id="CD007024-list-0012"> <li> <p>Cognitive behavioural psychotherapy (<a href="./references#CD007024-bbs2-0003" title="CarrollKM , BallSA , McCanceE , RounsavilleB . Treatment for cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction1998;93(5):713-28. ">Carroll 1998 dataset a</a>; <a href="./references#CD007024-bbs2-0005" title="CarrollKM , FentonLR , BallSA , NichCN , FrankforterTL , ShiJ , et al. Efficacy of Disulfiram and cognitive behavioral therapy in cocaine-dependent outpatients. Archives of General Psychiatry2004;61:264-72. ">Carroll 2004 dataset a</a>; <a href="./references#CD007024-bbs2-0012" title="GrassiMC , CioceAM , GiudiciFD , AntonilliL , NenciniP . Short-term efficacy of disulfiram or naltrexone in reducing positive urinalysis for both cocaine and cocaethylene in cocaine abusers: a pilot study. Pharmacological Research2007;55(2):117-21. ">Grassi 2007 dataset a</a>; <a href="./references#CD007024-bbs2-0013" title="GrassiMC , CioceAM , GiudiciFD , AntonilliL , NenciniP . Short-term efficacy of disulfiram or naltrexone in reducing positive urinalysis for both cocaine and cocaethylene in cocaine abusers: a pilot study. Pharmacological Research2007;55(2):117-21. ">Grassi 2007 dataset b</a>; <a href="./references#CD007024-bbs2-0014" title="KampangkaewJP , SpellicyCJ , NielsenEM , HardingMJ , YeA , HamonSC , et al. Pharmacogenetic role of dopamine transporter (SLC6A3) variation on response to disulfiram treatment for cocaine addiction. American Journal on Addictions 2019 Jul;28(4):311-7. KostenTR , WuG , HuangW , HardingMJ , HamonSC , LappalainenJ , et al. Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine beta-hydroxylase. Biological Psychiatry2013;73(3):219-24. NCT00000278. Disulfiram for cocaine-alcohol abuse - 3. clinicaltrials.gov/show/NCT00000278 (first received 21 September 1999). NCT00149630. Pharmacogenetics of disulfiram for cocaine. clinicaltrials.gov/show/NCT00149630 (first received 8 September 2005). NCT00729300. A study of the relationship between disulfiram and cocaine self-administration. clinicaltrials.gov/show/NCT00729300 (first received 7 August 2008). NielsenD , HuangW , HardingM , HamonS , LindsayJ , KostenT . Interaction of specific genetic variants with treatment effectiveness in disulfiram pharmacotherapy for cocaine dependence. In: Neuropsychopharmacology. Vol. 35. 2010:S341. NielsenDA , HardingMJ , HamonSC , HuangW , KostenTR . Modifying the role of serotonergic 5-HTTLPR and TPH2 variants on disulfiram treatment of cocaine addiction: a preliminary study. Genes, Brain and Behavior2012;11(8):1001-8. ShorterD , NielsenDA , HuangW , HardingMJ , HamonSC , KostenTR . Pharmacogenetic randomized trial for cocaine abuse: disulfiram and a1-adrenoceptor gene variation. European Neuropsychopharmacology2013;23(11):1401-7. SpellicyCJ , KostenTR , HamonSC , HardingMJ , NielsenDA . ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse. Pharmacogenetics and Genomics2013;23(7):333-40. SpellicyCJ , KostenTR , HamonSC , HardingMJ , NielsenDA . The MTHFR C677T variant is associated with responsiveness to disulfiram treatment for cocaine dependency. Frontiers in Psychiatry2013;3:109. [DOI: 10.3389/fpsyt.2012.00109]Thomas PS Jr, NielsenEM , SpellicyCJ , HardingMJ , YeA , PatriquinM , et al. The OPRD1 rs678849 variant influences outcome of disulfiram treatment for cocaine dependency in methadone-maintained patients. Psychiatric Genetics2021;31(3):88-94. ">Kosten 2013</a>; <a href="./references#CD007024-bbs2-0015" title="AtkinsonTS , SandersN , MancinoM , OlivetoA . Effects of disulfiram on QTc interval in non-opioid-dependent and methadone-treated cocaine-dependent patients. Journal of Addiction Medicine2013;7(4):243-8. [DOI: 10.1097/ADM.0b013e3182928e02]NCT00395850. Disulfiram for cocaine abuse. clinicaltrials.gov/show/NCT00395850 (first received 2 November 2006). NCT00580827. Clinical efficacy of disulfiram in LAAM-maintained cocaine abusers. clinicaltrials.gov/show/ NCT00580827 (first received 27 December 2007). OlivetoA , PolingJ , MancinoMJ , FeldmanZ , CubellsJF , PruzinskyR , et al. Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drugs and Alcohol Dependence2011;113(2-3):184-91. ">Oliveto 2011 dataset a</a>; <a href="./references#CD007024-bbs2-0016" title="NCT00395850. Disulfiram for Cocaine Abuse. clinicaltrials.gov/show/ NCT00395850 (first received 2 November 2006). [ClinicalTrials.gov Identifier: NCT00395850.]OlivetoA , PolingJ , MancinoMJ , FeldmanZ , CubellsJF , PruzinskyR , et al. Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drugs and Alcohol Dependence2011;113(2-3):184-91. ">Oliveto 2011 dataset b</a>; <a href="./references#CD007024-bbs2-0017" title="NCT00395850. Disulfiram for cocaine abuse. clinicaltrials.gov/show/ NCT00395850;(first received 2 November 2006). OlivetoA , PolingJ , MancinoMJ , FeldmanZ , CubellsJF , PruzinskyR , et al. Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drugs and Alcohol Dependence2011;113(2-3):184-91. ">Oliveto 2011 dataset c</a>; <a href="./references#CD007024-bbs2-0019" title="NCT00142844. Combination of disulfiram plus naltrexone to treat both cocaine- and alcohol-dependent individuals - 1 [Two medications, disulfiram and naltrexone, in the treatment of patients with both cocaine and alcohol dependence]. clinicaltrials.gov/show/NCT00142844 (first received 2 September 2005). [Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1 - Full Text View - ClinicalTrials.gov]PettinatiHM , KampmanKM , LynchKG , XieH , DackisC , RabinowitzAR , et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addictive Behaviors2008;33(5):651-67. ">Pettinati 2008 dataset a</a>; <a href="./references#CD007024-bbs2-0020" title="PettinatiHM , KampmanKM , LynchKG , XieH , DackisC , RabinowitzAR , et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addictive Behaviors2008;33(5):651-67. ">Pettinati 2008 dataset b</a>) </p> </li> <li> <p>Contingency management (<a href="./references#CD007024-bbs2-0009" title="CarrollKM , NichC , PetryNM , EaganDA , ShiJM , &amp; BallSA . A randomized factorial trial of disulfiram and contingency management to enhance cognitive behavioral therapy for cocaine dependence. Drug and Alcohol Dependence2016;160:135-42. De VitoEE , DongG , KoberH , XuJ , CarrollK , PotenzaMN . Neural effects of treatment in a trial of behavioral therapies and disulfiram for cocaine dependence. In: Drug and Alcohol Dependence. Vol. 171. 2017:e54. DeVitoEE , DongG , KoberH , XuJ , CarrollKM , PotenzaMN . Functional neural changes following behavioral therapies and disulfiram for cocaine dependence. Psychology of Addictive Behaviors2017;31:534. NCT00350870. CBT with disulfiram and contingency management. clinicaltrials.gov/show/NCT00350870 (first received 11 July 2006). ">Carroll 2016 dataset a</a>) </p> </li> <li> <p>Motivational intervention (<a href="./references#CD007024-bbs2-0001" title="ACTRN12611000103965. Disulfiram for the treatment of crack dependence. A pilot study. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000103965 (first received 31 January 2012). BaldaçaraL , DinizTA , ParreiraBL , MilhomemJJ , AlmeidaLJ , FernandesCC . Could disulfiram be a new treatment for crack cocaine dependence? A pilot study. Brazilian Journal of Psychiatry2013;35:97-8. ">Baldacara 2013</a>) </p> </li> <li> <p>12‐step facilitation (<a href="./references#CD007024-bbs2-0004" title="CarrollKM , BallSA , McCanceE , RounsavilleB . Treatment for cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction1998;93(5):713-28. ">Carroll 1998 dataset b</a>; <a href="./references#CD007024-bbs2-0007" title="CarrollKM , NichC , ShiJM , EaganD , BallSA . Efficacy of disulfiram and Twelve Step Facilitation in cocaine-dependent individuals maintained on methadone: a randomized placebo-controlled trial. Drug and Alcohol Dependence2012;126:224-31. ">Carroll 2012 dataset a</a>) </p> </li> <li> <p>Interpersonal psychotherapy (<a href="./references#CD007024-bbs2-0006" title="CarrollKM , FentonLR , BallSA , NichCN , FrankforterTL , ShiJ , et al. Efficacy of Disulfiram and cognitive behavioral therapy in cocaine-dependent outpatients. Archives of General Psychiatry2004;61:264-72. ">Carroll 2004 dataset b</a>) </p> </li> <li> <p>Counselling (<a href="./references#CD007024-bbs2-0058" title="GeorgeTP , ChawarskiMC , PakesJ , CarrollKM , KostenTR , SchottenfeldRS . Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial. Biological Psychiatry2000;47(12):1080-6.">George 2000</a>; <a href="./references#CD007024-bbs2-0085" title="PetrakisIL , CarrollKM , NichC , GordonLT , McCance-KatzEF , FrankforterT , et al. Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction2000;95(2):219-28.">Petrakis 2000</a>; <a href="./references#CD007024-bbs2-0021" title="NCT00913484. Disulfiram for cocaine abuse in buprenorphine treatment. clinicaltrials.gov/show/ NCT00913484 (first received 4 June 2009). SchottenfeldRS , ChawarskiMC , CubellsJF , GeorgeTP , LappalainenJ , KostenTR . Randomized clinical trial of disulfiram for cocaine dependence or abuse during buprenorphine treatment. Drug and Alcohol Dependence2013;136:36-42. ">Schottenfeld 2013</a>). </p> </li> </ul> </p> </section> <section id="CD007024-sec-0045"> <h5 class="title">Duration of trials</h5> <p>The mean duration of the trials was 11.7 weeks (range 8 weeks to 12 weeks).</p> </section> <section id="CD007024-sec-0046"> <h5 class="title">Country</h5> <p>Eleven RCTs were conducted in the USA. One RCT was from Brazil (<a href="./references#CD007024-bbs2-0001" title="ACTRN12611000103965. Disulfiram for the treatment of crack dependence. A pilot study. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000103965 (first received 31 January 2012). BaldaçaraL , DinizTA , ParreiraBL , MilhomemJJ , AlmeidaLJ , FernandesCC . Could disulfiram be a new treatment for crack cocaine dependence? A pilot study. Brazilian Journal of Psychiatry2013;35:97-8. ">Baldacara 2013</a>), and one was from Italy (<a href="./references#CD007024-bbs2-0012" title="GrassiMC , CioceAM , GiudiciFD , AntonilliL , NenciniP . Short-term efficacy of disulfiram or naltrexone in reducing positive urinalysis for both cocaine and cocaethylene in cocaine abusers: a pilot study. Pharmacological Research2007;55(2):117-21. ">Grassi 2007 dataset a</a>; <a href="./references#CD007024-bbs2-0013" title="GrassiMC , CioceAM , GiudiciFD , AntonilliL , NenciniP . Short-term efficacy of disulfiram or naltrexone in reducing positive urinalysis for both cocaine and cocaethylene in cocaine abusers: a pilot study. Pharmacological Research2007;55(2):117-21. ">Grassi 2007 dataset b</a>). All the RCTs were conducted in an outpatient setting. </p> </section> <section id="CD007024-sec-0047"> <h5 class="title">Amount of cocaine use</h5> <p>There were several units of measurement for amount of cocaine use: weight in grams (<a href="./references#CD007024-bbs2-0001" title="ACTRN12611000103965. Disulfiram for the treatment of crack dependence. A pilot study. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000103965 (first received 31 January 2012). BaldaçaraL , DinizTA , ParreiraBL , MilhomemJJ , AlmeidaLJ , FernandesCC . Could disulfiram be a new treatment for crack cocaine dependence? A pilot study. Brazilian Journal of Psychiatry2013;35:97-8. ">Baldacara 2013</a>; <a href="./references#CD007024-bbs2-0002" title="CarrollK , ZiedonisD , O'MalleyS , McCance-KatzE , GordonL , RounsavilleB . Pharmacological interventions for alcohol- and cocaine-abusing individuals: a pilot study of disulfiram vs. naltrexone. American Journal on Addictions1993;2:77-9. ">Carroll 1993</a>; <a href="./references#CD007024-bbs2-0018" title="PetrakisIL , CarrollKM , NichC , GordonLT , McCance-KatzEF , FrankforteT , et al. Disulfiram treatment for cocaine dependence in Methadone maintained opioid addicts. Addiction2000;95(2):219-28. ">Petrakis 2000</a>), weight expressed in bags or dimes (<a href="./references#CD007024-bbs2-0011" title="GeorgeTP , ChawarskiMC , PakesJ , CarrollKM , KostenTDR , SchottenfeldRS . Disulfiram versus placebo for cocaine dependence in Buprenorhine-mantained subjects: a preliminary trial. Biological Psychiatry2000;47:1080-6. ">George 2000</a>; <a href="./references#CD007024-bbs2-0019" title="NCT00142844. Combination of disulfiram plus naltrexone to treat both cocaine- and alcohol-dependent individuals - 1 [Two medications, disulfiram and naltrexone, in the treatment of patients with both cocaine and alcohol dependence]. clinicaltrials.gov/show/NCT00142844 (first received 2 September 2005). [Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1 - Full Text View - ClinicalTrials.gov]PettinatiHM , KampmanKM , LynchKG , XieH , DackisC , RabinowitzAR , et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addictive Behaviors2008;33(5):651-67. ">Pettinati 2008 dataset a</a>; <a href="./references#CD007024-bbs2-0020" title="PettinatiHM , KampmanKM , LynchKG , XieH , DackisC , RabinowitzAR , et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addictive Behaviors2008;33(5):651-67. ">Pettinati 2008 dataset b</a>), and money spent on purchasing cocaine (<a href="./references#CD007024-bbs2-0021" title="NCT00913484. Disulfiram for cocaine abuse in buprenorphine treatment. clinicaltrials.gov/show/ NCT00913484 (first received 4 June 2009). SchottenfeldRS , ChawarskiMC , CubellsJF , GeorgeTP , LappalainenJ , KostenTR . Randomized clinical trial of disulfiram for cocaine dependence or abuse during buprenorphine treatment. Drug and Alcohol Dependence2013;136:36-42. ">Schottenfeld 2013</a>). </p> </section> <section id="CD007024-sec-0048"> <h5 class="title">Rating instruments</h5> <p> <ul id="CD007024-list-0013"> <li> <p>Hamilton Anxiety Rating Scale (<a href="./references#CD007024-bbs2-0061" title="HamiltonM . The assessment of anxiety states by rating. British Journal of Psychiatry1959;32:50-5.">Hamilton 1959</a>; score ranging from 0 to 56, with higher scores indicating higher levels of anxiety) to measure the severity of anxiety symptoms: one RCT (<a href="./references#CD007024-bbs2-0019" title="NCT00142844. Combination of disulfiram plus naltrexone to treat both cocaine- and alcohol-dependent individuals - 1 [Two medications, disulfiram and naltrexone, in the treatment of patients with both cocaine and alcohol dependence]. clinicaltrials.gov/show/NCT00142844 (first received 2 September 2005). [Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1 - Full Text View - ClinicalTrials.gov]PettinatiHM , KampmanKM , LynchKG , XieH , DackisC , RabinowitzAR , et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addictive Behaviors2008;33(5):651-67. ">Pettinati 2008 dataset a</a>; <a href="./references#CD007024-bbs2-0020" title="PettinatiHM , KampmanKM , LynchKG , XieH , DackisC , RabinowitzAR , et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addictive Behaviors2008;33(5):651-67. ">Pettinati 2008 dataset b</a>) </p> </li> <li> <p>Hamilton Depression Rating Scale (<a href="./references#CD007024-bbs2-0062" title="HamiltonM . A rating scale for depression. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry1960;23:56-62.">Hamilton 1960</a>; score ranging from 0 to 52, with higher scores indicating higher levels of depression) to measure the severity of depression symptoms: one RCT (<a href="./references#CD007024-bbs2-0019" title="NCT00142844. Combination of disulfiram plus naltrexone to treat both cocaine- and alcohol-dependent individuals - 1 [Two medications, disulfiram and naltrexone, in the treatment of patients with both cocaine and alcohol dependence]. clinicaltrials.gov/show/NCT00142844 (first received 2 September 2005). [Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1 - Full Text View - ClinicalTrials.gov]PettinatiHM , KampmanKM , LynchKG , XieH , DackisC , RabinowitzAR , et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addictive Behaviors2008;33(5):651-67. ">Pettinati 2008 dataset a</a>; <a href="./references#CD007024-bbs2-0020" title="PettinatiHM , KampmanKM , LynchKG , XieH , DackisC , RabinowitzAR , et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addictive Behaviors2008;33(5):651-67. ">Pettinati 2008 dataset b</a>) </p> </li> <li> <p>Structured Clinical Interview for DSM‐III‐R (<a href="./references#CD007024-bbs2-0097" title="SpitzerRL , WilliamsJB , GibbonM , FirstMB . Structured Clinical Interview for DSM-III-R, Patient Edition/Non-patient Edition (SCID-P/SCID-NP). 1990 edition. Washington, D.C.: American Psychiatric Press, Inc., 1990.">Spitzer 1990</a>; <a href="./references#CD007024-bbs2-0098" title="SpitzerRL , WilliamsJB , GibbonM , FirstMB . The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description. Archives of General Psychiatry1992;49(8):624-9.">Spitzer 1992</a>) for the diagnosis of cocaine dependence, alcohol dependence, and opioid dependence: two RCTs (<a href="./references#CD007024-bbs2-0003" title="CarrollKM , BallSA , McCanceE , RounsavilleB . Treatment for cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction1998;93(5):713-28. ">Carroll 1998 dataset a</a>; <a href="./references#CD007024-bbs2-0004" title="CarrollKM , BallSA , McCanceE , RounsavilleB . Treatment for cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction1998;93(5):713-28. ">Carroll 1998 dataset b</a>; <a href="./references#CD007024-bbs2-0085" title="PetrakisIL , CarrollKM , NichC , GordonLT , McCance-KatzEF , FrankforterT , et al. Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction2000;95(2):219-28.">Petrakis 2000</a>) </p> </li> <li> <p>Structured Clinical Interview for DSM‐IV (<a href="./references#CD007024-bbs2-0056" title="FirstMB , SpitzerRL , GibbonM , WilliamsJB . Structured Clinical Interview for DSM-IV, Patient Edition. 1995 edition. Washington, DC: American Psychiatric Press, 1995.">First 1995</a>) for the diagnosis of cocaine dependence, alcohol dependence, and opioid dependence: six RCTs (<a href="./references#CD007024-bbs2-0005" title="CarrollKM , FentonLR , BallSA , NichCN , FrankforterTL , ShiJ , et al. Efficacy of Disulfiram and cognitive behavioral therapy in cocaine-dependent outpatients. Archives of General Psychiatry2004;61:264-72. ">Carroll 2004 dataset a</a>; <a href="./references#CD007024-bbs2-0006" title="CarrollKM , FentonLR , BallSA , NichCN , FrankforterTL , ShiJ , et al. Efficacy of Disulfiram and cognitive behavioral therapy in cocaine-dependent outpatients. Archives of General Psychiatry2004;61:264-72. ">Carroll 2004 dataset b</a>; <a href="./references#CD007024-bbs2-0007" title="CarrollKM , NichC , ShiJM , EaganD , BallSA . Efficacy of disulfiram and Twelve Step Facilitation in cocaine-dependent individuals maintained on methadone: a randomized placebo-controlled trial. Drug and Alcohol Dependence2012;126:224-31. ">Carroll 2012 dataset a</a>; <a href="./references#CD007024-bbs2-0008" title="CarrollKM , NichC , ShiJM , EaganD , BallSA . Efficacy of disulfiram and Twelve Step Facilitation in cocaine-dependent individuals maintained on methadone: a randomized placebo-controlled trial. Drug and Alcohol Dependence2012;126:224-31. ">Carroll 2012 dataset b</a>; <a href="./references#CD007024-bbs2-0009" title="CarrollKM , NichC , PetryNM , EaganDA , ShiJM , &amp; BallSA . A randomized factorial trial of disulfiram and contingency management to enhance cognitive behavioral therapy for cocaine dependence. Drug and Alcohol Dependence2016;160:135-42. De VitoEE , DongG , KoberH , XuJ , CarrollK , PotenzaMN . Neural effects of treatment in a trial of behavioral therapies and disulfiram for cocaine dependence. In: Drug and Alcohol Dependence. Vol. 171. 2017:e54. DeVitoEE , DongG , KoberH , XuJ , CarrollKM , PotenzaMN . Functional neural changes following behavioral therapies and disulfiram for cocaine dependence. Psychology of Addictive Behaviors2017;31:534. NCT00350870. CBT with disulfiram and contingency management. clinicaltrials.gov/show/NCT00350870 (first received 11 July 2006). ">Carroll 2016 dataset a</a>; <a href="./references#CD007024-bbs2-0010" title="CarrollKM , NichC , PetryNM , EaganDA , ShiJM , BallSA . A randomized factorial trial of disulfiram and contingency management to enhance cognitive behavioral therapy for cocaine dependence. Drug and Alcohol Dependence2016;160:135-42. DeVitoEE , DongG , KoberH , XuJ , CarrollKM , PotenzaMN . Functional neural changes following behavioral therapies and disulfiram for cocaine dependence. Psychology of Addictive Behavior2017;31:534. ">Carroll 2016 dataset b</a>; <a href="./references#CD007024-bbs2-0015" title="AtkinsonTS , SandersN , MancinoM , OlivetoA . Effects of disulfiram on QTc interval in non-opioid-dependent and methadone-treated cocaine-dependent patients. Journal of Addiction Medicine2013;7(4):243-8. [DOI: 10.1097/ADM.0b013e3182928e02]NCT00395850. Disulfiram for cocaine abuse. clinicaltrials.gov/show/NCT00395850 (first received 2 November 2006). NCT00580827. Clinical efficacy of disulfiram in LAAM-maintained cocaine abusers. clinicaltrials.gov/show/ NCT00580827 (first received 27 December 2007). OlivetoA , PolingJ , MancinoMJ , FeldmanZ , CubellsJF , PruzinskyR , et al. Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drugs and Alcohol Dependence2011;113(2-3):184-91. ">Oliveto 2011 dataset a</a>; <a href="./references#CD007024-bbs2-0016" title="NCT00395850. Disulfiram for Cocaine Abuse. clinicaltrials.gov/show/ NCT00395850 (first received 2 November 2006). [ClinicalTrials.gov Identifier: NCT00395850.]OlivetoA , PolingJ , MancinoMJ , FeldmanZ , CubellsJF , PruzinskyR , et al. Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drugs and Alcohol Dependence2011;113(2-3):184-91. ">Oliveto 2011 dataset b</a>; <a href="./references#CD007024-bbs2-0017" title="NCT00395850. Disulfiram for cocaine abuse. clinicaltrials.gov/show/ NCT00395850;(first received 2 November 2006). OlivetoA , PolingJ , MancinoMJ , FeldmanZ , CubellsJF , PruzinskyR , et al. Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drugs and Alcohol Dependence2011;113(2-3):184-91. ">Oliveto 2011 dataset c</a>; <a href="./references#CD007024-bbs2-0019" title="NCT00142844. Combination of disulfiram plus naltrexone to treat both cocaine- and alcohol-dependent individuals - 1 [Two medications, disulfiram and naltrexone, in the treatment of patients with both cocaine and alcohol dependence]. clinicaltrials.gov/show/NCT00142844 (first received 2 September 2005). [Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1 - Full Text View - ClinicalTrials.gov]PettinatiHM , KampmanKM , LynchKG , XieH , DackisC , RabinowitzAR , et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addictive Behaviors2008;33(5):651-67. ">Pettinati 2008 dataset a</a>; <a href="./references#CD007024-bbs2-0020" title="PettinatiHM , KampmanKM , LynchKG , XieH , DackisC , RabinowitzAR , et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addictive Behaviors2008;33(5):651-67. ">Pettinati 2008 dataset b</a>; <a href="./references#CD007024-bbs2-0021" title="NCT00913484. Disulfiram for cocaine abuse in buprenorphine treatment. clinicaltrials.gov/show/ NCT00913484 (first received 4 June 2009). SchottenfeldRS , ChawarskiMC , CubellsJF , GeorgeTP , LappalainenJ , KostenTR . Randomized clinical trial of disulfiram for cocaine dependence or abuse during buprenorphine treatment. Drug and Alcohol Dependence2013;136:36-42. ">Schottenfeld 2013</a>) </p> </li> <li> <p>Substance Abuse Calendar (similar to the Timeline Followback method; <a href="./references#CD007024-bbs2-0089" title="RobinsonSM , SobellLC , SobellMB , LeoGI . Reliability of the timeline followback for cocaine, cannabis, and cigarette use. Psychology of Addictive Behaviors2012;28:154-62.">Robinson 2012</a>) to measure cocaine use, frequency of cocaine use, continuous abstinence from cocaine, and point abstinence from cocaine: two RCTs (<a href="./references#CD007024-bbs2-0005" title="CarrollKM , FentonLR , BallSA , NichCN , FrankforterTL , ShiJ , et al. Efficacy of Disulfiram and cognitive behavioral therapy in cocaine-dependent outpatients. Archives of General Psychiatry2004;61:264-72. ">Carroll 2004 dataset a</a>; <a href="./references#CD007024-bbs2-0006" title="CarrollKM , FentonLR , BallSA , NichCN , FrankforterTL , ShiJ , et al. Efficacy of Disulfiram and cognitive behavioral therapy in cocaine-dependent outpatients. Archives of General Psychiatry2004;61:264-72. ">Carroll 2004 dataset b</a>; <a href="./references#CD007024-bbs2-0009" title="CarrollKM , NichC , PetryNM , EaganDA , ShiJM , &amp; BallSA . A randomized factorial trial of disulfiram and contingency management to enhance cognitive behavioral therapy for cocaine dependence. Drug and Alcohol Dependence2016;160:135-42. De VitoEE , DongG , KoberH , XuJ , CarrollK , PotenzaMN . Neural effects of treatment in a trial of behavioral therapies and disulfiram for cocaine dependence. In: Drug and Alcohol Dependence. Vol. 171. 2017:e54. DeVitoEE , DongG , KoberH , XuJ , CarrollKM , PotenzaMN . Functional neural changes following behavioral therapies and disulfiram for cocaine dependence. Psychology of Addictive Behaviors2017;31:534. NCT00350870. CBT with disulfiram and contingency management. clinicaltrials.gov/show/NCT00350870 (first received 11 July 2006). ">Carroll 2016 dataset a</a>; <a href="./references#CD007024-bbs2-0010" title="CarrollKM , NichC , PetryNM , EaganDA , ShiJM , BallSA . A randomized factorial trial of disulfiram and contingency management to enhance cognitive behavioral therapy for cocaine dependence. Drug and Alcohol Dependence2016;160:135-42. DeVitoEE , DongG , KoberH , XuJ , CarrollKM , PotenzaMN . Functional neural changes following behavioral therapies and disulfiram for cocaine dependence. Psychology of Addictive Behavior2017;31:534. ">Carroll 2016 dataset b</a>) </p> </li> <li> <p>Systematic Assessment for Treatment Emergent Effect to measure adverse events (<a href="./references#CD007024-bbs2-0087" title="RabkinJG , MarkowitzJS , Ocepek-WeliksonK , WagerSS . General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research. Journal of Clinical Psychopharmacology1992;12(1):3-10.">Rabkin 1992</a>): one RCT (<a href="./references#CD007024-bbs2-0019" title="NCT00142844. Combination of disulfiram plus naltrexone to treat both cocaine- and alcohol-dependent individuals - 1 [Two medications, disulfiram and naltrexone, in the treatment of patients with both cocaine and alcohol dependence]. clinicaltrials.gov/show/NCT00142844 (first received 2 September 2005). [Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1 - Full Text View - ClinicalTrials.gov]PettinatiHM , KampmanKM , LynchKG , XieH , DackisC , RabinowitzAR , et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addictive Behaviors2008;33(5):651-67. ">Pettinati 2008 dataset a</a>; <a href="./references#CD007024-bbs2-0020" title="PettinatiHM , KampmanKM , LynchKG , XieH , DackisC , RabinowitzAR , et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addictive Behaviors2008;33(5):651-67. ">Pettinati 2008 dataset b</a>) </p> </li> <li> <p>Timeline Followback method (TLFB; <a href="./references#CD007024-bbs2-0095" title="SobellLC , SobellMB . Timeline follow-back: A technique for assessing self-reported alcohol consumption. In: Allen J (Ed) Measuring Alcohol Consumption. Humana Press Inc, 1992:41-65.">Sobell 1992</a>) to measure cocaine use, frequency of cocaine use, continuous abstinence from cocaine, and point abstinence from cocaine: two RCTs (<a href="./references#CD007024-bbs2-0019" title="NCT00142844. Combination of disulfiram plus naltrexone to treat both cocaine- and alcohol-dependent individuals - 1 [Two medications, disulfiram and naltrexone, in the treatment of patients with both cocaine and alcohol dependence]. clinicaltrials.gov/show/NCT00142844 (first received 2 September 2005). [Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1 - Full Text View - ClinicalTrials.gov]PettinatiHM , KampmanKM , LynchKG , XieH , DackisC , RabinowitzAR , et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addictive Behaviors2008;33(5):651-67. ">Pettinati 2008 dataset a</a>; <a href="./references#CD007024-bbs2-0020" title="PettinatiHM , KampmanKM , LynchKG , XieH , DackisC , RabinowitzAR , et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addictive Behaviors2008;33(5):651-67. ">Pettinati 2008 dataset b</a>; <a href="./references#CD007024-bbs2-0021" title="NCT00913484. Disulfiram for cocaine abuse in buprenorphine treatment. clinicaltrials.gov/show/ NCT00913484 (first received 4 June 2009). SchottenfeldRS , ChawarskiMC , CubellsJF , GeorgeTP , LappalainenJ , KostenTR . Randomized clinical trial of disulfiram for cocaine dependence or abuse during buprenorphine treatment. Drug and Alcohol Dependence2013;136:36-42. ">Schottenfeld 2013</a>) </p> </li> <li> <p>Visual Analogue Scale (VAS; <a href="./references#CD007024-bbs2-0083" title="NicholsonAN . Visual analogues scales and drug effects in man. British Journal of Clinical Pharmacology1978;6:3-4.">Nicholson 1978</a>; score ranging from 0 to 100, with higher scores indicating higher levels of craving) to measure the severity of craving for cocaine: one RCT (<a href="./references#CD007024-bbs2-0012" title="GrassiMC , CioceAM , GiudiciFD , AntonilliL , NenciniP . Short-term efficacy of disulfiram or naltrexone in reducing positive urinalysis for both cocaine and cocaethylene in cocaine abusers: a pilot study. Pharmacological Research2007;55(2):117-21. ">Grassi 2007 dataset a</a>; <a href="./references#CD007024-bbs2-0013" title="GrassiMC , CioceAM , GiudiciFD , AntonilliL , NenciniP . Short-term efficacy of disulfiram or naltrexone in reducing positive urinalysis for both cocaine and cocaethylene in cocaine abusers: a pilot study. Pharmacological Research2007;55(2):117-21. ">Grassi 2007 dataset b</a>). </p> </li> </ul> </p> </section> <section id="CD007024-sec-0049"> <h5 class="title">Comparisons</h5> <p> <ul id="CD007024-list-0014"> <li> <p>Disulfiram versus placebo or no pharmacological treatment: 12 RCTs, 18 datasets, 1060 participants (<a href="./references#CD007024-bbs2-0001" title="ACTRN12611000103965. Disulfiram for the treatment of crack dependence. A pilot study. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000103965 (first received 31 January 2012). BaldaçaraL , DinizTA , ParreiraBL , MilhomemJJ , AlmeidaLJ , FernandesCC . Could disulfiram be a new treatment for crack cocaine dependence? A pilot study. Brazilian Journal of Psychiatry2013;35:97-8. ">Baldacara 2013</a>; <a href="./references#CD007024-bbs2-0003" title="CarrollKM , BallSA , McCanceE , RounsavilleB . Treatment for cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction1998;93(5):713-28. ">Carroll 1998 dataset a</a>; <a href="./references#CD007024-bbs2-0004" title="CarrollKM , BallSA , McCanceE , RounsavilleB . Treatment for cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction1998;93(5):713-28. ">Carroll 1998 dataset b</a>; <a href="./references#CD007024-bbs2-0005" title="CarrollKM , FentonLR , BallSA , NichCN , FrankforterTL , ShiJ , et al. Efficacy of Disulfiram and cognitive behavioral therapy in cocaine-dependent outpatients. Archives of General Psychiatry2004;61:264-72. ">Carroll 2004 dataset a</a>; <a href="./references#CD007024-bbs2-0006" title="CarrollKM , FentonLR , BallSA , NichCN , FrankforterTL , ShiJ , et al. Efficacy of Disulfiram and cognitive behavioral therapy in cocaine-dependent outpatients. Archives of General Psychiatry2004;61:264-72. ">Carroll 2004 dataset b</a>; <a href="./references#CD007024-bbs2-0007" title="CarrollKM , NichC , ShiJM , EaganD , BallSA . Efficacy of disulfiram and Twelve Step Facilitation in cocaine-dependent individuals maintained on methadone: a randomized placebo-controlled trial. Drug and Alcohol Dependence2012;126:224-31. ">Carroll 2012 dataset a</a>; <a href="./references#CD007024-bbs2-0008" title="CarrollKM , NichC , ShiJM , EaganD , BallSA . Efficacy of disulfiram and Twelve Step Facilitation in cocaine-dependent individuals maintained on methadone: a randomized placebo-controlled trial. Drug and Alcohol Dependence2012;126:224-31. ">Carroll 2012 dataset b</a>; <a href="./references#CD007024-bbs2-0009" title="CarrollKM , NichC , PetryNM , EaganDA , ShiJM , &amp; BallSA . A randomized factorial trial of disulfiram and contingency management to enhance cognitive behavioral therapy for cocaine dependence. Drug and Alcohol Dependence2016;160:135-42. De VitoEE , DongG , KoberH , XuJ , CarrollK , PotenzaMN . Neural effects of treatment in a trial of behavioral therapies and disulfiram for cocaine dependence. In: Drug and Alcohol Dependence. Vol. 171. 2017:e54. DeVitoEE , DongG , KoberH , XuJ , CarrollKM , PotenzaMN . Functional neural changes following behavioral therapies and disulfiram for cocaine dependence. Psychology of Addictive Behaviors2017;31:534. NCT00350870. CBT with disulfiram and contingency management. clinicaltrials.gov/show/NCT00350870 (first received 11 July 2006). ">Carroll 2016 dataset a</a>; <a href="./references#CD007024-bbs2-0010" title="CarrollKM , NichC , PetryNM , EaganDA , ShiJM , BallSA . A randomized factorial trial of disulfiram and contingency management to enhance cognitive behavioral therapy for cocaine dependence. Drug and Alcohol Dependence2016;160:135-42. DeVitoEE , DongG , KoberH , XuJ , CarrollKM , PotenzaMN . Functional neural changes following behavioral therapies and disulfiram for cocaine dependence. Psychology of Addictive Behavior2017;31:534. ">Carroll 2016 dataset b</a>; <a href="./references#CD007024-bbs2-0011" title="GeorgeTP , ChawarskiMC , PakesJ , CarrollKM , KostenTDR , SchottenfeldRS . Disulfiram versus placebo for cocaine dependence in Buprenorhine-mantained subjects: a preliminary trial. Biological Psychiatry2000;47:1080-6. ">George 2000</a>; <a href="./references#CD007024-bbs2-0012" title="GrassiMC , CioceAM , GiudiciFD , AntonilliL , NenciniP . Short-term efficacy of disulfiram or naltrexone in reducing positive urinalysis for both cocaine and cocaethylene in cocaine abusers: a pilot study. Pharmacological Research2007;55(2):117-21. ">Grassi 2007 dataset a</a>; <a href="./references#CD007024-bbs2-0014" title="KampangkaewJP , SpellicyCJ , NielsenEM , HardingMJ , YeA , HamonSC , et al. Pharmacogenetic role of dopamine transporter (SLC6A3) variation on response to disulfiram treatment for cocaine addiction. American Journal on Addictions 2019 Jul;28(4):311-7. KostenTR , WuG , HuangW , HardingMJ , HamonSC , LappalainenJ , et al. Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine beta-hydroxylase. Biological Psychiatry2013;73(3):219-24. NCT00000278. Disulfiram for cocaine-alcohol abuse - 3. clinicaltrials.gov/show/NCT00000278 (first received 21 September 1999). NCT00149630. Pharmacogenetics of disulfiram for cocaine. clinicaltrials.gov/show/NCT00149630 (first received 8 September 2005). NCT00729300. A study of the relationship between disulfiram and cocaine self-administration. clinicaltrials.gov/show/NCT00729300 (first received 7 August 2008). NielsenD , HuangW , HardingM , HamonS , LindsayJ , KostenT . Interaction of specific genetic variants with treatment effectiveness in disulfiram pharmacotherapy for cocaine dependence. In: Neuropsychopharmacology. Vol. 35. 2010:S341. NielsenDA , HardingMJ , HamonSC , HuangW , KostenTR . Modifying the role of serotonergic 5-HTTLPR and TPH2 variants on disulfiram treatment of cocaine addiction: a preliminary study. Genes, Brain and Behavior2012;11(8):1001-8. ShorterD , NielsenDA , HuangW , HardingMJ , HamonSC , KostenTR . Pharmacogenetic randomized trial for cocaine abuse: disulfiram and a1-adrenoceptor gene variation. European Neuropsychopharmacology2013;23(11):1401-7. SpellicyCJ , KostenTR , HamonSC , HardingMJ , NielsenDA . ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse. Pharmacogenetics and Genomics2013;23(7):333-40. SpellicyCJ , KostenTR , HamonSC , HardingMJ , NielsenDA . The MTHFR C677T variant is associated with responsiveness to disulfiram treatment for cocaine dependency. Frontiers in Psychiatry2013;3:109. [DOI: 10.3389/fpsyt.2012.00109]Thomas PS Jr, NielsenEM , SpellicyCJ , HardingMJ , YeA , PatriquinM , et al. The OPRD1 rs678849 variant influences outcome of disulfiram treatment for cocaine dependency in methadone-maintained patients. Psychiatric Genetics2021;31(3):88-94. ">Kosten 2013</a>; <a href="./references#CD007024-bbs2-0015" title="AtkinsonTS , SandersN , MancinoM , OlivetoA . Effects of disulfiram on QTc interval in non-opioid-dependent and methadone-treated cocaine-dependent patients. Journal of Addiction Medicine2013;7(4):243-8. [DOI: 10.1097/ADM.0b013e3182928e02]NCT00395850. Disulfiram for cocaine abuse. clinicaltrials.gov/show/NCT00395850 (first received 2 November 2006). NCT00580827. Clinical efficacy of disulfiram in LAAM-maintained cocaine abusers. clinicaltrials.gov/show/ NCT00580827 (first received 27 December 2007). OlivetoA , PolingJ , MancinoMJ , FeldmanZ , CubellsJF , PruzinskyR , et al. Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drugs and Alcohol Dependence2011;113(2-3):184-91. ">Oliveto 2011 dataset a</a>; <a href="./references#CD007024-bbs2-0016" title="NCT00395850. Disulfiram for Cocaine Abuse. clinicaltrials.gov/show/ NCT00395850 (first received 2 November 2006). [ClinicalTrials.gov Identifier: NCT00395850.]OlivetoA , PolingJ , MancinoMJ , FeldmanZ , CubellsJF , PruzinskyR , et al. Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drugs and Alcohol Dependence2011;113(2-3):184-91. ">Oliveto 2011 dataset b</a>; <a href="./references#CD007024-bbs2-0017" title="NCT00395850. Disulfiram for cocaine abuse. clinicaltrials.gov/show/ NCT00395850;(first received 2 November 2006). OlivetoA , PolingJ , MancinoMJ , FeldmanZ , CubellsJF , PruzinskyR , et al. Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drugs and Alcohol Dependence2011;113(2-3):184-91. ">Oliveto 2011 dataset c</a>; <a href="./references#CD007024-bbs2-0018" title="PetrakisIL , CarrollKM , NichC , GordonLT , McCance-KatzEF , FrankforteT , et al. Disulfiram treatment for cocaine dependence in Methadone maintained opioid addicts. Addiction2000;95(2):219-28. ">Petrakis 2000</a>; <a href="./references#CD007024-bbs2-0019" title="NCT00142844. Combination of disulfiram plus naltrexone to treat both cocaine- and alcohol-dependent individuals - 1 [Two medications, disulfiram and naltrexone, in the treatment of patients with both cocaine and alcohol dependence]. clinicaltrials.gov/show/NCT00142844 (first received 2 September 2005). [Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1 - Full Text View - ClinicalTrials.gov]PettinatiHM , KampmanKM , LynchKG , XieH , DackisC , RabinowitzAR , et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addictive Behaviors2008;33(5):651-67. ">Pettinati 2008 dataset a</a>; <a href="./references#CD007024-bbs2-0021" title="NCT00913484. Disulfiram for cocaine abuse in buprenorphine treatment. clinicaltrials.gov/show/ NCT00913484 (first received 4 June 2009). SchottenfeldRS , ChawarskiMC , CubellsJF , GeorgeTP , LappalainenJ , KostenTR . Randomized clinical trial of disulfiram for cocaine dependence or abuse during buprenorphine treatment. Drug and Alcohol Dependence2013;136:36-42. ">Schottenfeld 2013</a>) </p> </li> <li> <p>Disulfiram versus naltrexone: three RCTs, 131 participants (<a href="./references#CD007024-bbs2-0002" title="CarrollK , ZiedonisD , O'MalleyS , McCance-KatzE , GordonL , RounsavilleB . Pharmacological interventions for alcohol- and cocaine-abusing individuals: a pilot study of disulfiram vs. naltrexone. American Journal on Addictions1993;2:77-9. ">Carroll 1993</a>; <a href="./references#CD007024-bbs2-0013" title="GrassiMC , CioceAM , GiudiciFD , AntonilliL , NenciniP . Short-term efficacy of disulfiram or naltrexone in reducing positive urinalysis for both cocaine and cocaethylene in cocaine abusers: a pilot study. Pharmacological Research2007;55(2):117-21. ">Grassi 2007 dataset b</a>; <a href="./references#CD007024-bbs2-0020" title="PettinatiHM , KampmanKM , LynchKG , XieH , DackisC , RabinowitzAR , et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addictive Behaviors2008;33(5):651-67. ">Pettinati 2008 dataset b</a>). </p> </li> </ul> </p> </section> <section id="CD007024-sec-0050"> <h5 class="title">Subgroup analyses</h5> <p>We performed the following subgroup analyses.</p> <p> <ul id="CD007024-list-0015"> <li> <p>Comorbid alcohol dependence</p> </li> <li> <p>Comorbid opioid dependence</p> </li> </ul> </p> </section> </section> <section id="CD007024-sec-0051"> <h4 class="title">Excluded studies</h4> <p>We excluded 13 studies (see <a href="./references#CD007024-sec-0132" title="">Characteristics of excluded studies</a>). </p> </section> </section> <section id="CD007024-sec-0052"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD007024-fig-0002">Figure 2</a> and <a href="#CD007024-fig-0003">Figure 3</a> for a summary of these results. </p> <div class="figure" id="CD007024-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies." data-id="CD007024-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD007024-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD007024-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD007024-sec-0053"> <h4 class="title">Allocation</h4> <section id="CD007024-sec-0054"> <h5 class="title">Random sequence generation</h5> <p>We judged six RCTs at low risk of selection bias for random sequence generation and the remaining RCTs at unclear risk (the publications provided no information on the method of sequence generation). </p> </section> <section id="CD007024-sec-0055"> <h5 class="title">Allocation concealment</h5> <p>We considered 11 RCTs at unclear risk for allocation concealment, as they provided no information. The other two RCTs were at low risk of bias in this domain. </p> </section> </section> <section id="CD007024-sec-0056"> <h4 class="title">Blinding</h4> <section id="CD007024-sec-0057"> <h5 class="title">Blinding of participants and personnel (performance bias)</h5> <p>Our risk of bias judgements were identical for selective and objective outcomes. We judged three RCTs at high risk of performance bias because they had an open‐label design. Two RCTs were described as double‐blind trials but provided no further details (unclear risk of bias). We considered the remaining RCTs at low risk of performance bias. </p> </section> <section id="CD007024-sec-0058"> <h5 class="title">Blinding of outcome assessor (detection bias)</h5> <p>For subjective outcomes, we judged three RCTs at high risk of detection bias, two at unclear risk, and six at low risk. </p> <p>For objective outcomes, we considered all RCTs at low risk of detection bias as the outcomes were unlikely to be influenced by lack of blinding. </p> </section> </section> <section id="CD007024-sec-0059"> <h4 class="title">Incomplete outcome data</h4> <p>All the RCTs were at low risk of attrition bias because they analysed all randomised participants in the arm to which they were randomised (intention‐to‐treat approach). </p> </section> <section id="CD007024-sec-0060"> <h4 class="title">Selective reporting</h4> <p>The protocol was available for four RCTs; however, two of these protocols did not clearly describe the outcomes. Therefore, we judged only two RCTs at low risk for selective reporting because all the outcomes listed in the protocols were assessed and reported in the final publications. We considered one RCT at high risk and eight RCTs at unclear risk. </p> </section> </section> <section id="CD007024-sec-0061"> <h3 class="title" id="CD007024-sec-0061">Effects of interventions</h3> <p>See: <a href="./full#CD007024-tbl-0001"><b>Summary of findings 1</b> Summary of findings table – disulfiram compared to placebo or no pharmacological treatment for people with cocaine dependence</a>; <a href="./full#CD007024-tbl-0002"><b>Summary of findings 2</b> Summary of findings table – disulfiram compared to naltrexone for people with cocaine dependence</a> </p> <section id="CD007024-sec-0062"> <h4 class="title">Comparison 1. Disulfiram versus placebo or no pharmacological treatment</h4> <section id="CD007024-sec-0063"> <h5 class="title">Primary outcomes</h5> <p>See <a href="./full#CD007024-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD007024-sec-0064"> <h6 class="title">Frequency of cocaine use</h6> <p>We included 13 datasets (818 participants) in this meta‐analysis (<a href="./references#CD007024-bbs2-0001" title="ACTRN12611000103965. Disulfiram for the treatment of crack dependence. A pilot study. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000103965 (first received 31 January 2012). BaldaçaraL , DinizTA , ParreiraBL , MilhomemJJ , AlmeidaLJ , FernandesCC . Could disulfiram be a new treatment for crack cocaine dependence? A pilot study. Brazilian Journal of Psychiatry2013;35:97-8. ">Baldacara 2013</a>; <a href="./references#CD007024-bbs2-0003" title="CarrollKM , BallSA , McCanceE , RounsavilleB . Treatment for cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction1998;93(5):713-28. ">Carroll 1998 dataset a</a>; <a href="./references#CD007024-bbs2-0004" title="CarrollKM , BallSA , McCanceE , RounsavilleB . Treatment for cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction1998;93(5):713-28. ">Carroll 1998 dataset b</a>; <a href="./references#CD007024-bbs2-0005" title="CarrollKM , FentonLR , BallSA , NichCN , FrankforterTL , ShiJ , et al. Efficacy of Disulfiram and cognitive behavioral therapy in cocaine-dependent outpatients. Archives of General Psychiatry2004;61:264-72. ">Carroll 2004 dataset a</a>; <a href="./references#CD007024-bbs2-0006" title="CarrollKM , FentonLR , BallSA , NichCN , FrankforterTL , ShiJ , et al. Efficacy of Disulfiram and cognitive behavioral therapy in cocaine-dependent outpatients. Archives of General Psychiatry2004;61:264-72. ">Carroll 2004 dataset b</a>; <a href="./references#CD007024-bbs2-0007" title="CarrollKM , NichC , ShiJM , EaganD , BallSA . Efficacy of disulfiram and Twelve Step Facilitation in cocaine-dependent individuals maintained on methadone: a randomized placebo-controlled trial. Drug and Alcohol Dependence2012;126:224-31. ">Carroll 2012 dataset a</a>; <a href="./references#CD007024-bbs2-0008" title="CarrollKM , NichC , ShiJM , EaganD , BallSA . Efficacy of disulfiram and Twelve Step Facilitation in cocaine-dependent individuals maintained on methadone: a randomized placebo-controlled trial. Drug and Alcohol Dependence2012;126:224-31. ">Carroll 2012 dataset b</a>; <a href="./references#CD007024-bbs2-0009" title="CarrollKM , NichC , PetryNM , EaganDA , ShiJM , &amp; BallSA . A randomized factorial trial of disulfiram and contingency management to enhance cognitive behavioral therapy for cocaine dependence. Drug and Alcohol Dependence2016;160:135-42. De VitoEE , DongG , KoberH , XuJ , CarrollK , PotenzaMN . Neural effects of treatment in a trial of behavioral therapies and disulfiram for cocaine dependence. In: Drug and Alcohol Dependence. Vol. 171. 2017:e54. DeVitoEE , DongG , KoberH , XuJ , CarrollKM , PotenzaMN . Functional neural changes following behavioral therapies and disulfiram for cocaine dependence. Psychology of Addictive Behaviors2017;31:534. NCT00350870. CBT with disulfiram and contingency management. clinicaltrials.gov/show/NCT00350870 (first received 11 July 2006). ">Carroll 2016 dataset a</a>; <a href="./references#CD007024-bbs2-0010" title="CarrollKM , NichC , PetryNM , EaganDA , ShiJM , BallSA . A randomized factorial trial of disulfiram and contingency management to enhance cognitive behavioral therapy for cocaine dependence. Drug and Alcohol Dependence2016;160:135-42. DeVitoEE , DongG , KoberH , XuJ , CarrollKM , PotenzaMN . Functional neural changes following behavioral therapies and disulfiram for cocaine dependence. Psychology of Addictive Behavior2017;31:534. ">Carroll 2016 dataset b</a>; <a href="./references#CD007024-bbs2-0011" title="GeorgeTP , ChawarskiMC , PakesJ , CarrollKM , KostenTDR , SchottenfeldRS . Disulfiram versus placebo for cocaine dependence in Buprenorhine-mantained subjects: a preliminary trial. Biological Psychiatry2000;47:1080-6. ">George 2000</a>; <a href="./references#CD007024-bbs2-0018" title="PetrakisIL , CarrollKM , NichC , GordonLT , McCance-KatzEF , FrankforteT , et al. Disulfiram treatment for cocaine dependence in Methadone maintained opioid addicts. Addiction2000;95(2):219-28. ">Petrakis 2000</a>; <a href="./references#CD007024-bbs2-0019" title="NCT00142844. Combination of disulfiram plus naltrexone to treat both cocaine- and alcohol-dependent individuals - 1 [Two medications, disulfiram and naltrexone, in the treatment of patients with both cocaine and alcohol dependence]. clinicaltrials.gov/show/NCT00142844 (first received 2 September 2005). [Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1 - Full Text View - ClinicalTrials.gov]PettinatiHM , KampmanKM , LynchKG , XieH , DackisC , RabinowitzAR , et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addictive Behaviors2008;33(5):651-67. ">Pettinati 2008 dataset a</a>; <a href="./references#CD007024-bbs2-0021" title="NCT00913484. Disulfiram for cocaine abuse in buprenorphine treatment. clinicaltrials.gov/show/ NCT00913484 (first received 4 June 2009). SchottenfeldRS , ChawarskiMC , CubellsJF , GeorgeTP , LappalainenJ , KostenTR . Randomized clinical trial of disulfiram for cocaine dependence or abuse during buprenorphine treatment. Drug and Alcohol Dependence2013;136:36-42. ">Schottenfeld 2013</a>). Disulfiram compared with placebo or no pharmacological treatment may have little or no effect on frequency of cocaine use (SMD −0.11 SDs, 95% CI −0.39 to 0.17; low‐certainty evidence). The meta‐analysis showed substantial heterogeneity (Tau² = 0.18; Chi² = 43.39, degrees of freedom (df) = 12 (P &lt; 0.001); I² = 72%). See <a href="./references#CD007024-fig-0010" title="">Analysis 1.1</a> and <a href="#CD007024-fig-0004">Figure 4</a>. Visual inspection of the funnel plot did not suggest publication bias (<a href="#CD007024-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD007024-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Disulfiram versus placebo or no pharmacological treatment; outcome: 1 Frequency of cocaine use (mean number of days or weeks of cocaine use at the end of treatment)." data-id="CD007024-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Disulfiram versus placebo or no pharmacological treatment; outcome: 1 Frequency of cocaine use (mean number of days or weeks of cocaine use at the end of treatment). </p> </div> </div> </div> <div class="figure" id="CD007024-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot for comparison: 1 Disulfiram versus placebo or no pharmacological treatment; outcome: 1 Frequency of cocaine use." data-id="CD007024-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot for comparison: 1 Disulfiram versus placebo or no pharmacological treatment; outcome: 1 Frequency of cocaine use. </p> </div> </div> </div> <section id="CD007024-sec-0065"> <p><b>Subgroup analysis: comparator</b></p> <p>The test for subgroup difference suggested a significant difference in the effect according to the type of comparator (P = 0.002). The subgroup analysis suggested that disulfiram increased the frequency of cocaine use compared to no pharmacological treatment (SMD 0.57 SDs, 95% CI 0.14 to 0.99; 2 datasets, 90 participants) but had little or no effect compared to placebo (<a href="./references#CD007024-fig-0010" title="">Analysis 1.1</a>). </p> </section> <section id="CD007024-sec-0066"> <p><b>Subgroup analysis: comorbid alcohol dependence</b></p> <p>The test for subgroup difference suggested a significant difference in the effect according to the presence of alcohol dependence (Chi² = 12.09, df = 2 (P = 0.002), I² = 83.5%). The subgroup analysis suggested that disulfiram reduced the frequency of cocaine use among participants without alcohol dependence (SMD −1.60 SDs, 95% CI −2.56 to −0.64; 2 studies, 50 participants), but not among participants with comorbid alcohol dependence, or in datasets that included people with and without alcohol dependence (<a href="./references#CD007024-fig-0029" title="">Analysis 3.1</a>). </p> </section> <section id="CD007024-sec-0067"> <p><b>Subgroup analysis: comorbid opioid dependence</b></p> <p>All participants with comorbid opioid dependence received treatment with opioid agonists (methadone or buprenorphine). We found no differences between subgroups according to the presence of comorbid opioid dependence in opioid agonist treatment (Chi² = 1.08, df = 1 (P = 0.30), I² = 7.3%; <a href="./references#CD007024-fig-0030" title="">Analysis 3.2</a>) </p> </section> </section> <section id="CD007024-sec-0068"> <h6 class="title">Amount of cocaine use</h6> <p>We included seven datasets (376 participants) in this meta‐analysis (<a href="./references#CD007024-bbs2-0001" title="ACTRN12611000103965. Disulfiram for the treatment of crack dependence. A pilot study. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000103965 (first received 31 January 2012). BaldaçaraL , DinizTA , ParreiraBL , MilhomemJJ , AlmeidaLJ , FernandesCC . Could disulfiram be a new treatment for crack cocaine dependence? A pilot study. Brazilian Journal of Psychiatry2013;35:97-8. ">Baldacara 2013</a>; <a href="./references#CD007024-bbs2-0011" title="GeorgeTP , ChawarskiMC , PakesJ , CarrollKM , KostenTDR , SchottenfeldRS . Disulfiram versus placebo for cocaine dependence in Buprenorhine-mantained subjects: a preliminary trial. Biological Psychiatry2000;47:1080-6. ">George 2000</a>; <a href="./references#CD007024-bbs2-0015" title="AtkinsonTS , SandersN , MancinoM , OlivetoA . Effects of disulfiram on QTc interval in non-opioid-dependent and methadone-treated cocaine-dependent patients. Journal of Addiction Medicine2013;7(4):243-8. [DOI: 10.1097/ADM.0b013e3182928e02]NCT00395850. Disulfiram for cocaine abuse. clinicaltrials.gov/show/NCT00395850 (first received 2 November 2006). NCT00580827. Clinical efficacy of disulfiram in LAAM-maintained cocaine abusers. clinicaltrials.gov/show/ NCT00580827 (first received 27 December 2007). OlivetoA , PolingJ , MancinoMJ , FeldmanZ , CubellsJF , PruzinskyR , et al. Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drugs and Alcohol Dependence2011;113(2-3):184-91. ">Oliveto 2011 dataset a</a>; <a href="./references#CD007024-bbs2-0016" title="NCT00395850. Disulfiram for Cocaine Abuse. clinicaltrials.gov/show/ NCT00395850 (first received 2 November 2006). [ClinicalTrials.gov Identifier: NCT00395850.]OlivetoA , PolingJ , MancinoMJ , FeldmanZ , CubellsJF , PruzinskyR , et al. Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drugs and Alcohol Dependence2011;113(2-3):184-91. ">Oliveto 2011 dataset b</a>; <a href="./references#CD007024-bbs2-0017" title="NCT00395850. Disulfiram for cocaine abuse. clinicaltrials.gov/show/ NCT00395850;(first received 2 November 2006). OlivetoA , PolingJ , MancinoMJ , FeldmanZ , CubellsJF , PruzinskyR , et al. Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drugs and Alcohol Dependence2011;113(2-3):184-91. ">Oliveto 2011 dataset c</a>; <a href="./references#CD007024-bbs2-0018" title="PetrakisIL , CarrollKM , NichC , GordonLT , McCance-KatzEF , FrankforteT , et al. Disulfiram treatment for cocaine dependence in Methadone maintained opioid addicts. Addiction2000;95(2):219-28. ">Petrakis 2000</a>; <a href="./references#CD007024-bbs2-0019" title="NCT00142844. Combination of disulfiram plus naltrexone to treat both cocaine- and alcohol-dependent individuals - 1 [Two medications, disulfiram and naltrexone, in the treatment of patients with both cocaine and alcohol dependence]. clinicaltrials.gov/show/NCT00142844 (first received 2 September 2005). [Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1 - Full Text View - ClinicalTrials.gov]PettinatiHM , KampmanKM , LynchKG , XieH , DackisC , RabinowitzAR , et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addictive Behaviors2008;33(5):651-67. ">Pettinati 2008 dataset a</a>). Disulfiram compared to placebo may have little or no effect on amount of cocaine use (SMD −0.00 SDs, 95% CI −0.30 to 0.30; low‐certainty evidence). There was moderate heterogeneity between the datasets (Tau² = 0.07; Chi² = 10.62, df = 6 (P = 0.10); I² = 44%). See <a href="./references#CD007024-fig-0011" title="">Analysis 1.2</a> and <a href="#CD007024-fig-0006">Figure 6</a>. </p> <div class="figure" id="CD007024-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Disulfiram versus placebo or no pharmacological treatment; outcome: 2 Amount of cocaine use (mean weight of cocaine used or money spent on cocaine at the end of treatment)" data-id="CD007024-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Disulfiram versus placebo or no pharmacological treatment; outcome: 2 Amount of cocaine use (mean weight of cocaine used or money spent on cocaine at the end of treatment) </p> </div> </div> </div> </section> <section id="CD007024-sec-0069"> <h6 class="title">Continuous abstinence from cocaine</h6> <p>We included six datasets (386 participants) in this meta‐analysis (<a href="./references#CD007024-bbs2-0003" title="CarrollKM , BallSA , McCanceE , RounsavilleB . Treatment for cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction1998;93(5):713-28. ">Carroll 1998 dataset a</a>; <a href="./references#CD007024-bbs2-0004" title="CarrollKM , BallSA , McCanceE , RounsavilleB . Treatment for cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction1998;93(5):713-28. ">Carroll 1998 dataset b</a>; <a href="./references#CD007024-bbs2-0009" title="CarrollKM , NichC , PetryNM , EaganDA , ShiJM , &amp; BallSA . A randomized factorial trial of disulfiram and contingency management to enhance cognitive behavioral therapy for cocaine dependence. Drug and Alcohol Dependence2016;160:135-42. De VitoEE , DongG , KoberH , XuJ , CarrollK , PotenzaMN . Neural effects of treatment in a trial of behavioral therapies and disulfiram for cocaine dependence. In: Drug and Alcohol Dependence. Vol. 171. 2017:e54. DeVitoEE , DongG , KoberH , XuJ , CarrollKM , PotenzaMN . Functional neural changes following behavioral therapies and disulfiram for cocaine dependence. Psychology of Addictive Behaviors2017;31:534. NCT00350870. CBT with disulfiram and contingency management. clinicaltrials.gov/show/NCT00350870 (first received 11 July 2006). ">Carroll 2016 dataset a</a>; <a href="./references#CD007024-bbs2-0010" title="CarrollKM , NichC , PetryNM , EaganDA , ShiJM , BallSA . A randomized factorial trial of disulfiram and contingency management to enhance cognitive behavioral therapy for cocaine dependence. Drug and Alcohol Dependence2016;160:135-42. DeVitoEE , DongG , KoberH , XuJ , CarrollKM , PotenzaMN . Functional neural changes following behavioral therapies and disulfiram for cocaine dependence. Psychology of Addictive Behavior2017;31:534. ">Carroll 2016 dataset b</a>; <a href="./references#CD007024-bbs2-0011" title="GeorgeTP , ChawarskiMC , PakesJ , CarrollKM , KostenTDR , SchottenfeldRS . Disulfiram versus placebo for cocaine dependence in Buprenorhine-mantained subjects: a preliminary trial. Biological Psychiatry2000;47:1080-6. ">George 2000</a>; <a href="./references#CD007024-bbs2-0021" title="NCT00913484. Disulfiram for cocaine abuse in buprenorphine treatment. clinicaltrials.gov/show/ NCT00913484 (first received 4 June 2009). SchottenfeldRS , ChawarskiMC , CubellsJF , GeorgeTP , LappalainenJ , KostenTR . Randomized clinical trial of disulfiram for cocaine dependence or abuse during buprenorphine treatment. Drug and Alcohol Dependence2013;136:36-42. ">Schottenfeld 2013</a>). Disulfiram compared to placebo or no pharmacological treatment may have little or no effect on continuous abstinence from cocaine (RR 1.23, 95% CI 0.80 to 1.91; low‐certainty evidence). The results of statistical tests suggested low or moderate heterogeneity between the datasets (Tau² = 0.11; Chi² = 8.02, df = 5 (P = 0.16); I² = 38%). See <a href="./references#CD007024-fig-0012" title="">Analysis 1.3</a> and <a href="#CD007024-fig-0007">Figure 7</a>. </p> <div class="figure" id="CD007024-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Disulfiram versus placebo or no pharmacological treatment; outcome: 3 Continuous abstinence (number of participants who had achieved and maintained abstinence for at least three weeks at the end of treatment)" data-id="CD007024-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-FIG-07.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Disulfiram versus placebo or no pharmacological treatment; outcome: 3 Continuous abstinence (number of participants who had achieved and maintained abstinence for at least three weeks at the end of treatment) </p> </div> </div> </div> <section id="CD007024-sec-0070"> <p><b>Subgroup analysis: comparator</b></p> <p>The subgroup analysis did not show a difference in the intervention effect on continuous abstinence from cocaine according to the type of comparator (Chi² = 3.50, df = 1 (P = 0.06); I² = 71.4%). </p> </section> </section> <section id="CD007024-sec-0071"> <h6 class="title">Point abstinence from cocaine</h6> <p>We included three datasets (142 participants) in this meta‐analysis (<a href="./references#CD007024-bbs2-0001" title="ACTRN12611000103965. Disulfiram for the treatment of crack dependence. A pilot study. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000103965 (first received 31 January 2012). BaldaçaraL , DinizTA , ParreiraBL , MilhomemJJ , AlmeidaLJ , FernandesCC . Could disulfiram be a new treatment for crack cocaine dependence? A pilot study. Brazilian Journal of Psychiatry2013;35:97-8. ">Baldacara 2013</a>; <a href="./references#CD007024-bbs2-0007" title="CarrollKM , NichC , ShiJM , EaganD , BallSA . Efficacy of disulfiram and Twelve Step Facilitation in cocaine-dependent individuals maintained on methadone: a randomized placebo-controlled trial. Drug and Alcohol Dependence2012;126:224-31. ">Carroll 2012 dataset a</a>; <a href="./references#CD007024-bbs2-0008" title="CarrollKM , NichC , ShiJM , EaganD , BallSA . Efficacy of disulfiram and Twelve Step Facilitation in cocaine-dependent individuals maintained on methadone: a randomized placebo-controlled trial. Drug and Alcohol Dependence2012;126:224-31. ">Carroll 2012 dataset b</a>). Disulfiram compared to placebo may increase point abstinence (RR 1.58, 95% CI 1.05 to 2.36; low‐certainty evidence). There was no evidence of heterogeneity between the datasets (Tau² = 0.00; Chi² = 0.79, df = 2 (P = 0.67); I² = 0%). See <a href="./references#CD007024-fig-0013" title="">Analysis 1.4</a> and <a href="#CD007024-fig-0008">Figure 8</a>. </p> <div class="figure" id="CD007024-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Disulfiram versus placebo or no pharmacological treatment; outcome: 4 Point abstinence (number of participants who were abstinent at the end of treatment)." data-id="CD007024-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-FIG-08.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Disulfiram versus placebo or no pharmacological treatment; outcome: 4 Point abstinence (number of participants who were abstinent at the end of treatment). </p> </div> </div> </div> </section> <section id="CD007024-sec-0072"> <h6 class="title">Dropout for any reason</h6> <p>We included 14 datasets (841 participants) in this meta‐analysis (<a href="./references#CD007024-bbs2-0001" title="ACTRN12611000103965. Disulfiram for the treatment of crack dependence. A pilot study. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000103965 (first received 31 January 2012). BaldaçaraL , DinizTA , ParreiraBL , MilhomemJJ , AlmeidaLJ , FernandesCC . Could disulfiram be a new treatment for crack cocaine dependence? A pilot study. Brazilian Journal of Psychiatry2013;35:97-8. ">Baldacara 2013</a>; <a href="./references#CD007024-bbs2-0007" title="CarrollKM , NichC , ShiJM , EaganD , BallSA . Efficacy of disulfiram and Twelve Step Facilitation in cocaine-dependent individuals maintained on methadone: a randomized placebo-controlled trial. Drug and Alcohol Dependence2012;126:224-31. ">Carroll 2012 dataset a</a>; <a href="./references#CD007024-bbs2-0008" title="CarrollKM , NichC , ShiJM , EaganD , BallSA . Efficacy of disulfiram and Twelve Step Facilitation in cocaine-dependent individuals maintained on methadone: a randomized placebo-controlled trial. Drug and Alcohol Dependence2012;126:224-31. ">Carroll 2012 dataset b</a>; <a href="./references#CD007024-bbs2-0009" title="CarrollKM , NichC , PetryNM , EaganDA , ShiJM , &amp; BallSA . A randomized factorial trial of disulfiram and contingency management to enhance cognitive behavioral therapy for cocaine dependence. Drug and Alcohol Dependence2016;160:135-42. De VitoEE , DongG , KoberH , XuJ , CarrollK , PotenzaMN . Neural effects of treatment in a trial of behavioral therapies and disulfiram for cocaine dependence. In: Drug and Alcohol Dependence. Vol. 171. 2017:e54. DeVitoEE , DongG , KoberH , XuJ , CarrollKM , PotenzaMN . Functional neural changes following behavioral therapies and disulfiram for cocaine dependence. Psychology of Addictive Behaviors2017;31:534. NCT00350870. CBT with disulfiram and contingency management. clinicaltrials.gov/show/NCT00350870 (first received 11 July 2006). ">Carroll 2016 dataset a</a>; <a href="./references#CD007024-bbs2-0010" title="CarrollKM , NichC , PetryNM , EaganDA , ShiJM , BallSA . A randomized factorial trial of disulfiram and contingency management to enhance cognitive behavioral therapy for cocaine dependence. Drug and Alcohol Dependence2016;160:135-42. DeVitoEE , DongG , KoberH , XuJ , CarrollKM , PotenzaMN . Functional neural changes following behavioral therapies and disulfiram for cocaine dependence. Psychology of Addictive Behavior2017;31:534. ">Carroll 2016 dataset b</a>; <a href="./references#CD007024-bbs2-0011" title="GeorgeTP , ChawarskiMC , PakesJ , CarrollKM , KostenTDR , SchottenfeldRS . Disulfiram versus placebo for cocaine dependence in Buprenorhine-mantained subjects: a preliminary trial. Biological Psychiatry2000;47:1080-6. ">George 2000</a>; <a href="./references#CD007024-bbs2-0013" title="GrassiMC , CioceAM , GiudiciFD , AntonilliL , NenciniP . Short-term efficacy of disulfiram or naltrexone in reducing positive urinalysis for both cocaine and cocaethylene in cocaine abusers: a pilot study. Pharmacological Research2007;55(2):117-21. ">Grassi 2007 dataset b</a>; <a href="./references#CD007024-bbs2-0014" title="KampangkaewJP , SpellicyCJ , NielsenEM , HardingMJ , YeA , HamonSC , et al. Pharmacogenetic role of dopamine transporter (SLC6A3) variation on response to disulfiram treatment for cocaine addiction. American Journal on Addictions 2019 Jul;28(4):311-7. KostenTR , WuG , HuangW , HardingMJ , HamonSC , LappalainenJ , et al. Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine beta-hydroxylase. Biological Psychiatry2013;73(3):219-24. NCT00000278. Disulfiram for cocaine-alcohol abuse - 3. clinicaltrials.gov/show/NCT00000278 (first received 21 September 1999). NCT00149630. Pharmacogenetics of disulfiram for cocaine. clinicaltrials.gov/show/NCT00149630 (first received 8 September 2005). NCT00729300. A study of the relationship between disulfiram and cocaine self-administration. clinicaltrials.gov/show/NCT00729300 (first received 7 August 2008). NielsenD , HuangW , HardingM , HamonS , LindsayJ , KostenT . Interaction of specific genetic variants with treatment effectiveness in disulfiram pharmacotherapy for cocaine dependence. In: Neuropsychopharmacology. Vol. 35. 2010:S341. NielsenDA , HardingMJ , HamonSC , HuangW , KostenTR . Modifying the role of serotonergic 5-HTTLPR and TPH2 variants on disulfiram treatment of cocaine addiction: a preliminary study. Genes, Brain and Behavior2012;11(8):1001-8. ShorterD , NielsenDA , HuangW , HardingMJ , HamonSC , KostenTR . Pharmacogenetic randomized trial for cocaine abuse: disulfiram and a1-adrenoceptor gene variation. European Neuropsychopharmacology2013;23(11):1401-7. SpellicyCJ , KostenTR , HamonSC , HardingMJ , NielsenDA . ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse. Pharmacogenetics and Genomics2013;23(7):333-40. SpellicyCJ , KostenTR , HamonSC , HardingMJ , NielsenDA . The MTHFR C677T variant is associated with responsiveness to disulfiram treatment for cocaine dependency. Frontiers in Psychiatry2013;3:109. [DOI: 10.3389/fpsyt.2012.00109]Thomas PS Jr, NielsenEM , SpellicyCJ , HardingMJ , YeA , PatriquinM , et al. The OPRD1 rs678849 variant influences outcome of disulfiram treatment for cocaine dependency in methadone-maintained patients. Psychiatric Genetics2021;31(3):88-94. ">Kosten 2013</a>; <a href="./references#CD007024-bbs2-0015" title="AtkinsonTS , SandersN , MancinoM , OlivetoA . Effects of disulfiram on QTc interval in non-opioid-dependent and methadone-treated cocaine-dependent patients. Journal of Addiction Medicine2013;7(4):243-8. [DOI: 10.1097/ADM.0b013e3182928e02]NCT00395850. Disulfiram for cocaine abuse. clinicaltrials.gov/show/NCT00395850 (first received 2 November 2006). NCT00580827. Clinical efficacy of disulfiram in LAAM-maintained cocaine abusers. clinicaltrials.gov/show/ NCT00580827 (first received 27 December 2007). OlivetoA , PolingJ , MancinoMJ , FeldmanZ , CubellsJF , PruzinskyR , et al. Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drugs and Alcohol Dependence2011;113(2-3):184-91. ">Oliveto 2011 dataset a</a>; <a href="./references#CD007024-bbs2-0016" title="NCT00395850. Disulfiram for Cocaine Abuse. clinicaltrials.gov/show/ NCT00395850 (first received 2 November 2006). [ClinicalTrials.gov Identifier: NCT00395850.]OlivetoA , PolingJ , MancinoMJ , FeldmanZ , CubellsJF , PruzinskyR , et al. Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drugs and Alcohol Dependence2011;113(2-3):184-91. ">Oliveto 2011 dataset b</a>; <a href="./references#CD007024-bbs2-0017" title="NCT00395850. Disulfiram for cocaine abuse. clinicaltrials.gov/show/ NCT00395850;(first received 2 November 2006). OlivetoA , PolingJ , MancinoMJ , FeldmanZ , CubellsJF , PruzinskyR , et al. Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drugs and Alcohol Dependence2011;113(2-3):184-91. ">Oliveto 2011 dataset c</a>; <a href="./references#CD007024-bbs2-0018" title="PetrakisIL , CarrollKM , NichC , GordonLT , McCance-KatzEF , FrankforteT , et al. Disulfiram treatment for cocaine dependence in Methadone maintained opioid addicts. Addiction2000;95(2):219-28. ">Petrakis 2000</a>; <a href="./references#CD007024-bbs2-0019" title="NCT00142844. Combination of disulfiram plus naltrexone to treat both cocaine- and alcohol-dependent individuals - 1 [Two medications, disulfiram and naltrexone, in the treatment of patients with both cocaine and alcohol dependence]. clinicaltrials.gov/show/NCT00142844 (first received 2 September 2005). [Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1 - Full Text View - ClinicalTrials.gov]PettinatiHM , KampmanKM , LynchKG , XieH , DackisC , RabinowitzAR , et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addictive Behaviors2008;33(5):651-67. ">Pettinati 2008 dataset a</a>; <a href="./references#CD007024-bbs2-0021" title="NCT00913484. Disulfiram for cocaine abuse in buprenorphine treatment. clinicaltrials.gov/show/ NCT00913484 (first received 4 June 2009). SchottenfeldRS , ChawarskiMC , CubellsJF , GeorgeTP , LappalainenJ , KostenTR . Randomized clinical trial of disulfiram for cocaine dependence or abuse during buprenorphine treatment. Drug and Alcohol Dependence2013;136:36-42. ">Schottenfeld 2013</a>). Disulfiram compared with placebo or no pharmacological treatment may have little or no effect on dropout for any reason (RR 1.20, 95% CI 0.92 to 1.55; low‐certainty evidence). The results of statistical tests suggested low heterogeneity (Tau² = 0.03; Chi² = 14.96, df = 13 (P = 0.31); I² = 13%). See <a href="./references#CD007024-fig-0014" title="">Analysis 1.5</a>. Visual inspection of the funnel plot did not suggest publication bias (<a href="#CD007024-fig-0009">Figure 9</a>). </p> <div class="figure" id="CD007024-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Funnel plot for comparison: 1 Disulfiram versus placebo or no pharmacological treatment; outcome: 5 Dropout for any reason" data-id="CD007024-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-FIG-09.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot for comparison: 1 Disulfiram versus placebo or no pharmacological treatment; outcome: 5 Dropout for any reason </p> </div> </div> </div> <section id="CD007024-sec-0073"> <p><b>Subgroup analysis: comparator</b></p> <p>The subgroup analysis showed no difference in the intervention effect on dropout according to the type of comparator. </p> </section> <section id="CD007024-sec-0074"> <p><b>Subgroup analyses: comorbid alcohol dependence and comorbid opioid dependence</b></p> <p>We found no differences in the intervention effect according to the presence of comorbid alcohol dependence (Chi² = 0.39, df = 2 (P = 0.82), I² = 0%; <a href="./references#CD007024-fig-0031" title="">Analysis 3.3</a>) or opioid dependence (Chi² = 0.69, df = 1 (P = 0.41), I² = 0%; <a href="./references#CD007024-fig-0032" title="">Analysis 3.4</a>). All participants with comorbid opioid dependence received treatment with opioid agonists (methadone or buprenorphine). </p> </section> </section> <section id="CD007024-sec-0075"> <h6 class="title">Dropout due to adverse events</h6> <p>One RCT (67 participants) reported the number of participants who did not complete the treatment due to adverse events (<a href="./references#CD007024-bbs2-0018" title="PetrakisIL , CarrollKM , NichC , GordonLT , McCance-KatzEF , FrankforteT , et al. Disulfiram treatment for cocaine dependence in Methadone maintained opioid addicts. Addiction2000;95(2):219-28. ">Petrakis 2000</a>). Disulfiram compared to placebo may have little or no effect on dropout due to adverse events, but the evidence is very uncertain (RR 12.97, 95% CI 0.77 to 218.37; very low‐certainty evidence; <a href="./references#CD007024-fig-0015" title="">Analysis 1.6</a>). </p> </section> <section id="CD007024-sec-0076"> <h6 class="title">Any adverse events</h6> <p>One RCT (30 participants) reported the number of participants who experienced at least one adverse event (<a href="./references#CD007024-bbs2-0001" title="ACTRN12611000103965. Disulfiram for the treatment of crack dependence. A pilot study. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000103965 (first received 31 January 2012). BaldaçaraL , DinizTA , ParreiraBL , MilhomemJJ , AlmeidaLJ , FernandesCC . Could disulfiram be a new treatment for crack cocaine dependence? A pilot study. Brazilian Journal of Psychiatry2013;35:97-8. ">Baldacara 2013</a>). Disulfiram compared to placebo may have little or no effect on the occurrence of adverse events, but the evidence is very uncertain (RR 3.0, 95% CI 0.35 to 25.98), very low‐certainty evidence; <a href="./references#CD007024-fig-0016" title="">Analysis 1.7</a>). </p> </section> <section id="CD007024-sec-0077"> <h6 class="title">Serious adverse events</h6> <p>No RCTs reported the number of participants who experienced at least one serious adverse event. </p> </section> </section> <section id="CD007024-sec-0078"> <h5 class="title">Secondary outcomes</h5> <section id="CD007024-sec-0079"> <h6 class="title">Individual adverse events</h6> <p>We included one, two, or three datasets in the analysis of individual adverse events (<a href="./references#CD007024-bbs2-0001" title="ACTRN12611000103965. Disulfiram for the treatment of crack dependence. A pilot study. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000103965 (first received 31 January 2012). BaldaçaraL , DinizTA , ParreiraBL , MilhomemJJ , AlmeidaLJ , FernandesCC . Could disulfiram be a new treatment for crack cocaine dependence? A pilot study. Brazilian Journal of Psychiatry2013;35:97-8. ">Baldacara 2013</a>; <a href="./references#CD007024-bbs2-0003" title="CarrollKM , BallSA , McCanceE , RounsavilleB . Treatment for cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction1998;93(5):713-28. ">Carroll 1998 dataset a</a>; <a href="./references#CD007024-bbs2-0019" title="NCT00142844. Combination of disulfiram plus naltrexone to treat both cocaine- and alcohol-dependent individuals - 1 [Two medications, disulfiram and naltrexone, in the treatment of patients with both cocaine and alcohol dependence]. clinicaltrials.gov/show/NCT00142844 (first received 2 September 2005). [Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1 - Full Text View - ClinicalTrials.gov]PettinatiHM , KampmanKM , LynchKG , XieH , DackisC , RabinowitzAR , et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addictive Behaviors2008;33(5):651-67. ">Pettinati 2008 dataset a</a>). Evidence from <a href="./references#CD007024-bbs2-0019" title="NCT00142844. Combination of disulfiram plus naltrexone to treat both cocaine- and alcohol-dependent individuals - 1 [Two medications, disulfiram and naltrexone, in the treatment of patients with both cocaine and alcohol dependence]. clinicaltrials.gov/show/NCT00142844 (first received 2 September 2005). [Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1 - Full Text View - ClinicalTrials.gov]PettinatiHM , KampmanKM , LynchKG , XieH , DackisC , RabinowitzAR , et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addictive Behaviors2008;33(5):651-67. ">Pettinati 2008 dataset a</a> (109 participants) suggested that disulfiram compared to placebo may lower increased sexual desire (RR 0.41, 95% CI 0.17 to 0.97; <a href="./references#CD007024-fig-0017" title="">Analysis 1.8</a>). We found no difference between the effect of disulfiram and placebo on any of the other adverse events evaluated (headache, drowsiness/fatigue, anxiety/irritability, nausea, upper respiratory tract infections, decreased sexual desire, vomiting, skin rush, difficulty in achieving orgasm, toothache, diarrhoea, and slurred speech). </p> </section> <section id="CD007024-sec-0080"> <h6 class="title">Craving</h6> <p>Evidence from <a href="./references#CD007024-bbs2-0012" title="GrassiMC , CioceAM , GiudiciFD , AntonilliL , NenciniP . Short-term efficacy of disulfiram or naltrexone in reducing positive urinalysis for both cocaine and cocaethylene in cocaine abusers: a pilot study. Pharmacological Research2007;55(2):117-21. ">Grassi 2007 dataset a</a> (8 participants) suggested that disulfiram compared to no pharmacological treatment decreased craving measured on a VAS of 0 to 100 points (MD −25.00 points, 95% CI −44.52 to −5.48; <a href="./references#CD007024-fig-0018" title="">Analysis 1.9</a>). </p> </section> <section id="CD007024-sec-0081"> <h6 class="title">Severity of dependence</h6> <p>No RCTs reported severity of dependence.</p> </section> <section id="CD007024-sec-0082"> <h6 class="title">Psychiatric symptoms/psychological distress: depression</h6> <p>Evidence from <a href="./references#CD007024-bbs2-0019" title="NCT00142844. Combination of disulfiram plus naltrexone to treat both cocaine- and alcohol-dependent individuals - 1 [Two medications, disulfiram and naltrexone, in the treatment of patients with both cocaine and alcohol dependence]. clinicaltrials.gov/show/NCT00142844 (first received 2 September 2005). [Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1 - Full Text View - ClinicalTrials.gov]PettinatiHM , KampmanKM , LynchKG , XieH , DackisC , RabinowitzAR , et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addictive Behaviors2008;33(5):651-67. ">Pettinati 2008 dataset a</a> (107 participants) suggested no difference between the effect of disulfiram and placebo on depression measured by the Hamilton Depression Rating Scale, which ranges from 0 to 52 points (MD −1.00 points, 95% CI −4.13 to 2.13; <a href="./references#CD007024-fig-0019" title="">Analysis 1.10</a>). </p> </section> <section id="CD007024-sec-0083"> <h6 class="title">Psychiatric symptoms/psychological distress: anxiety</h6> <p>Evidence from <a href="./references#CD007024-bbs2-0019" title="NCT00142844. Combination of disulfiram plus naltrexone to treat both cocaine- and alcohol-dependent individuals - 1 [Two medications, disulfiram and naltrexone, in the treatment of patients with both cocaine and alcohol dependence]. clinicaltrials.gov/show/NCT00142844 (first received 2 September 2005). [Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1 - Full Text View - ClinicalTrials.gov]PettinatiHM , KampmanKM , LynchKG , XieH , DackisC , RabinowitzAR , et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addictive Behaviors2008;33(5):651-67. ">Pettinati 2008 dataset a</a> (107 participants) suggested no difference between the effect of disulfiram and placebo on anxiety measured by the Hamilton Anxiety Rating Scale, which ranges from 0 to 56 points (MD −1.50 points, 95% CI −4.78 to 1.78; <a href="./references#CD007024-fig-0020" title="">Analysis 1.11</a>). </p> </section> </section> </section> <section id="CD007024-sec-0084"> <h4 class="title">Comparison 2. Disulfiram versus naltrexone</h4> <section id="CD007024-sec-0085"> <h5 class="title">Primary outcomes</h5> <p>See <a href="./full#CD007024-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD007024-sec-0086"> <h6 class="title">Frequency of cocaine use</h6> <p>We included two datasets (123 participants) in this meta‐analysis (<a href="./references#CD007024-bbs2-0002" title="CarrollK , ZiedonisD , O'MalleyS , McCance-KatzE , GordonL , RounsavilleB . Pharmacological interventions for alcohol- and cocaine-abusing individuals: a pilot study of disulfiram vs. naltrexone. American Journal on Addictions1993;2:77-9. ">Carroll 1993</a>; <a href="./references#CD007024-bbs2-0020" title="PettinatiHM , KampmanKM , LynchKG , XieH , DackisC , RabinowitzAR , et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addictive Behaviors2008;33(5):651-67. ">Pettinati 2008 dataset b</a>). Disulfiram compared to naltrexone may reduce the frequency of cocaine use (MD −1.90 days, 95% CI −3.37 to −0.43; low‐certainty evidence). The results of statistical tests suggested low or moderate heterogeneity between the datasets (Tau² = 0.57; Chi² = 1.48, df = 1 (P = 0.22); I² = 32%). See <a href="./references#CD007024-fig-0021" title="">Analysis 2.1</a> </p> </section> <section id="CD007024-sec-0087"> <h6 class="title">Amount of cocaine use</h6> <p>We included two datasets (123 participants) in this meta‐analysis (<a href="./references#CD007024-bbs2-0002" title="CarrollK , ZiedonisD , O'MalleyS , McCance-KatzE , GordonL , RounsavilleB . Pharmacological interventions for alcohol- and cocaine-abusing individuals: a pilot study of disulfiram vs. naltrexone. American Journal on Addictions1993;2:77-9. ">Carroll 1993</a>; <a href="./references#CD007024-bbs2-0020" title="PettinatiHM , KampmanKM , LynchKG , XieH , DackisC , RabinowitzAR , et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addictive Behaviors2008;33(5):651-67. ">Pettinati 2008 dataset b</a>). Disulfiram compared to naltrexone may have little or no effect on amount of cocaine use (SMD 0.12 SDs, 95% CI −0.27 to 0.51; low‐certainty evidence). The results of statistical tests suggested low heterogeneity between the datasets (Tau² = 0.01; Chi² = 1.07, df = 1 (P = 0.30); I² = 7%). See <a href="./references#CD007024-fig-0022" title="">Analysis 2.2</a>. </p> </section> <section id="CD007024-sec-0088"> <h6 class="title">Continuous abstinence from cocaine</h6> <p>No RCTs reported continuous abstinence from cocaine.</p> </section> <section id="CD007024-sec-0089"> <h6 class="title">Point abstinence from cocaine</h6> <p>No RCTs reported point abstinence from cocaine.</p> </section> <section id="CD007024-sec-0090"> <h6 class="title">Dropout for any reason</h6> <p>We included three datasets (131 participants) in this meta‐analysis (<a href="./references#CD007024-bbs2-0002" title="CarrollK , ZiedonisD , O'MalleyS , McCance-KatzE , GordonL , RounsavilleB . Pharmacological interventions for alcohol- and cocaine-abusing individuals: a pilot study of disulfiram vs. naltrexone. American Journal on Addictions1993;2:77-9. ">Carroll 1993</a>; <a href="./references#CD007024-bbs2-0020" title="PettinatiHM , KampmanKM , LynchKG , XieH , DackisC , RabinowitzAR , et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addictive Behaviors2008;33(5):651-67. ">Pettinati 2008 dataset b</a>; <a href="./references#CD007024-bbs2-0013" title="GrassiMC , CioceAM , GiudiciFD , AntonilliL , NenciniP . Short-term efficacy of disulfiram or naltrexone in reducing positive urinalysis for both cocaine and cocaethylene in cocaine abusers: a pilot study. Pharmacological Research2007;55(2):117-21. ">Grassi 2007 dataset b</a>). Disulfiram compared to naltrexone may have little or no effect on the number of people who do not complete treatment (RR 0.86, 95% CI 0.56 to 1.32; very low‐certainty evidence). The results of statistical tests suggested low heterogeneity between the datasets (Tau² = 0.03; Chi² = 2.57, df = 2 (P = 0.28); I² = 22%). See <a href="./references#CD007024-fig-0023" title="">Analysis 2.3</a>. </p> </section> <section id="CD007024-sec-0091"> <h6 class="title">Dropout due to adverse events</h6> <p>Evidence from <a href="./references#CD007024-bbs2-0013" title="GrassiMC , CioceAM , GiudiciFD , AntonilliL , NenciniP . Short-term efficacy of disulfiram or naltrexone in reducing positive urinalysis for both cocaine and cocaethylene in cocaine abusers: a pilot study. Pharmacological Research2007;55(2):117-21. ">Grassi 2007 dataset b</a> (8 participants) suggested that disulfiram compared to naltrexone has no effect on the number of people who do not complete treatment due to adverse events, but the evidence is very uncertain (RR 0.50, 95% CI 0.07 to 3.55; very low‐certainty evidence; <a href="./references#CD007024-fig-0024" title="">Analysis 2.4</a>). </p> </section> <section id="CD007024-sec-0092"> <h6 class="title">Any adverse events</h6> <p>No RCTs reported the number of participants who experienced at least one adverse event.</p> </section> <section id="CD007024-sec-0093"> <h6 class="title">Serious adverse events</h6> <p>No RCTs reported the number of participants who experienced at least one serious adverse event. </p> </section> </section> <section id="CD007024-sec-0094"> <h5 class="title">Secondary outcomes</h5> <section id="CD007024-sec-0095"> <h6 class="title">Individual adverse events</h6> <p>We only included data from <a href="./references#CD007024-bbs2-0020" title="PettinatiHM , KampmanKM , LynchKG , XieH , DackisC , RabinowitzAR , et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addictive Behaviors2008;33(5):651-67. ">Pettinati 2008 dataset b</a> in the analyses of individual adverse events, finding no difference between the effect of disulfiram and naltrexone on the occurrence of headache, drowsiness/fatigue, anxiety, nausea, upper respiratory tract infection, decreased sexual desire, increased sexual desire, vomiting, skin rash, difficulty in achieving orgasm, toothache, or diarrhoea (<a href="./references#CD007024-fig-0025" title="">Analysis 2.5</a>). </p> </section> <section id="CD007024-sec-0096"> <h6 class="title">Craving</h6> <p>Evidence from <a href="./references#CD007024-bbs2-0013" title="GrassiMC , CioceAM , GiudiciFD , AntonilliL , NenciniP . Short-term efficacy of disulfiram or naltrexone in reducing positive urinalysis for both cocaine and cocaethylene in cocaine abusers: a pilot study. Pharmacological Research2007;55(2):117-21. ">Grassi 2007 dataset b</a> (8 participants) suggested there was no difference between the effect of disulfiram and naltrexone on craving measured on a VAS of 0 to 100 points (MD −1.02 points, 95% CI −16.73 to 14.69; <a href="./references#CD007024-fig-0026" title="">Analysis 2.6</a>). </p> </section> <section id="CD007024-sec-0097"> <h6 class="title">Severity of dependence</h6> <p>No RCTs reported severity of dependence.</p> </section> <section id="CD007024-sec-0098"> <h6 class="title">Psychiatric symptoms/psychological distress: depression</h6> <p>Evidence from <a href="./references#CD007024-bbs2-0020" title="PettinatiHM , KampmanKM , LynchKG , XieH , DackisC , RabinowitzAR , et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addictive Behaviors2008;33(5):651-67. ">Pettinati 2008 dataset b</a> (105 participants) suggested no difference between the effect of disulfiram and placebo on depression measured by the Hamilton Depression Rating Scale, which ranges from 0 to 52 points (MD −2.00 points, 95% CI −4.76 to 0.76; <a href="./references#CD007024-fig-0027" title="">Analysis 2.7</a>). </p> </section> <section id="CD007024-sec-0099"> <h6 class="title">Psychiatric symptoms/psychological distress: anxiety</h6> <p>Evidence from <a href="./references#CD007024-bbs2-0020" title="PettinatiHM , KampmanKM , LynchKG , XieH , DackisC , RabinowitzAR , et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addictive Behaviors2008;33(5):651-67. ">Pettinati 2008 dataset b</a> (105 participants) suggested no difference between the effect of disulfiram and placebo on anxiety measured by the Hamilton Anxiety Rating Scale, which ranges from 0 to 56 points (MD −1.00 points, 95% CI −4.27 to 2.27; <a href="./references#CD007024-fig-0028" title="">Analysis 2.8</a>). </p> </section> </section> <section id="CD007024-sec-0100"> <h5 class="title">Sensitivity analysis</h5> <p>We rated no RCTs at high risk of selection bias, so we were unable to perform our prespecified sensitivity analysis. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007024-sec-0101" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007024-sec-0101"></div> <section id="CD007024-sec-0102"> <h3 class="title" id="CD007024-sec-0102">Summary of main results</h3> <p>This review update included 13 RCTs with 1191 participants (71.2% males) compared to seven RCTs with 492 participants in the previous version (<a href="./references#CD007024-bbs2-0104" title="PaniPP , TroguE , VaccaR , AmatoL , VecchiS , DavoliM . Disulfiram for the treatment of cocaine dependence. Cochrane Database of Systematic Reviews2010, Issue 1. Art. No: CD007024. [DOI: 10.1002/14651858.CD007024.pub2]">Pani 2010</a>). We extracted a single dataset from six RCTs, two datasets from each of six RCTs, and three datasets from one RCT, for a total of 21 datasets. Twelve RCTs (18 datasets) with 1060 participants evaluated disulfiram versus placebo or no pharmacological treatment, and three RCTs (3 datasets) with 131 participants evaluated disulfiram versus naltrexone. </p> <section id="CD007024-sec-0103"> <h4 class="title">Disulfiram versus placebo or no pharmacological treatment</h4> <p>Compared to placebo, disulfiram may increase point abstinence from cocaine (the number of people who are abstinent at the end of treatment). However, disulfiram compared to placebo or no pharmacological treatment may have little or no effect on frequency of cocaine use, amount of cocaine use, continuous abstinence, or dropout for any reason. Subgroup analyses suggested that disulfiram reduces the frequency of cocaine use when compared to no pharmacological treatment but not when compared to placebo, and among people without alcohol dependence but not among people with alcohol dependence. However, these subgroup results included only two datasets each and limited numbers of participants (90 in comparator subgroup analysis, 50 in alcohol dependence subgroup analysis). We are uncertain about the effects of disulfiram compared to placebo on the number of people who drop out of treatment due to adverse events and on the number of people who experience at least one adverse event, as the evidence is of very low certainty. </p> <p>Studies have shown that by inhibiting the primary pathways for cocaine metabolism, disulfiram increases plasma cocaine concentration significantly more than placebo, and, depending on the dosage of the two compounds and the method of cocaine administration, may also increase heart rate and systolic and diastolic blood pressure (<a href="./references#CD007024-bbs2-0041" title="BakerJR , JatlowP , McCance-KatzEF . Disulfiram effects on responses to intravenous cocaine administration. Drug and Alcohol Dependence2007;87(2-3):202-9.">Baker 2007</a>; <a href="./references#CD007024-bbs2-0073" title="McCance-KatzEF , KostenTR , JatlowP . Disulfiram effects on acute cocaine administration. Drug and Alcohol Dependence1998;52(1):27-39.">McCance 1998a</a>; <a href="./references#CD007024-bbs2-0074" title="McCance-KatzEF , KostenTR , JatlowP . Chronic disulfiram treatment effects on intranasal cocaine administration: initial results. Biological Psychiatry1998;43(7):540-3.">McCance 1998b</a>). The inclusion criteria of the included RCTs took into account the risk of disulfiram and cocaine interactions. Some studies that specifically investigated these potential interactions reported that disulfiram‐cocaine interactions may not constitute a major problem (<a href="./references#CD007024-bbs2-0071" title="MalcolmR , OliveMF , LechnerW . The safety of disulfiram for the treatment of alcohol and cocaine dependence in randomized clinical trials: guidance for clinical practice. Expert Opinion on Drug Safety2008;7(4):459-72. [DOI: 10.1517/14740338.7.4.459]">Malcolm 2008</a>; <a href="./references#CD007024-bbs2-0088" title="RoacheJD , KahnR , NewtonTF , WallaceCL , MurffWL , De La Garza R 2nd, et al. A double-blind, placebo-controlled assessment of the safety of potential interactions between intravenous cocaine, ethanol, and oral disulfiram. Drug and Alcohol Dependence2011;119(1-2):37-45.">Roache 2011</a>). However, given the inconclusive evidence in clinical practice, clinicians should consider these risks when deciding whether to prescribe disulfiram to people with cocaine dependence (<a href="./references#CD007024-bbs2-0068" title="KleczkowskaP , SulejczakD , ZarembaM . Advantages and disadvantages of disulfiram coadministered with popular addictive substances. European Journal of Pharmacology2021;904:174143. [DOI: 10.1016/j.ejphar.2021.174143]">Kleczkowska 2021</a>). These potential interactions together with other adverse effects (i.e. hepatotoxicity, cardiovascular, and psychiatric complications) could worsen the safety profile of disulfiram in the treatment of cocaine dependence. </p> </section> <section id="CD007024-sec-0104"> <h4 class="title">Disulfiram versus naltrexone</h4> <p>Disulfiram compared to naltrexone may reduce the frequency of cocaine use, but may have little or no effect on the amount of cocaine use. We are uncertain about the effects of disulfiram compared to naltrexone on dropout for any reason and on dropout due to adverse events because the evidence is of very low certainty. </p> </section> </section> <section id="CD007024-sec-0105"> <h3 class="title" id="CD007024-sec-0105">Overall completeness and applicability of evidence</h3> <p>Overall, the 13 RCTs included in this update provide limited evidence on the efficacy of disulfiram compared with placebo, no pharmacological treatment, or naltrexone in terms of efficacy, acceptability, and safety. Owing to lack of data, we were able to perform subgroup analyses for only three outcomes. Most participants were males (72.1%). Eleven RCTs were conducted in the USA, most at Yale University. This limits the generalisability of the results, because gender, sex, and social context influence the severity of dependence, the availability to enter an experimental design, and the response to treatment; and because different clinical contexts can influence the selection of participants and the results of the treatment. Furthermore, the selected RCTs differed in terms of design, quality, characteristics of participants, services, and treatments delivered: four were open‐label studies; three compared disulfiram to naltrexone; four involved participants with comorbid alcohol dependence; six involved participants with comorbid opioid dependence co‐treated with methadone or buprenorphine; three offered drug counselling as an ancillary intervention, six offered cognitive behavioural therapy, two offered twelve‐step facilitation, one offered interpersonal psychotherapy, and one offered no specified individual psychotherapy. The trials also differed in their definitions of outcome variables, so we were not always able to pool data and carry out meta‐analyses and subgroup analyses. </p> </section> <section id="CD007024-sec-0106"> <h3 class="title" id="CD007024-sec-0106">Quality of the evidence</h3> <p>Applying the criteria recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007024-bbs2-0065" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>), we judged 75% of the RCTs at unclear risk of selection bias and 23% at high risk of performance bias and detection bias (subjective outcomes). </p> <p>Overall, comparing disulfiram to placebo or no pharmacological treatment, we rated the certainty of evidence as low or very low for all the primary outcomes considered. Reasons for downgrading were risk of bias, inconsistency, and imprecision of the overall estimates. Similarly, comparing disulfiram to naltrexone, we rated the evidence as low or very low for all the primary outcomes considered. Reasons for downgrading were risk of bias and imprecision of the overall estimates. </p> </section> <section id="CD007024-sec-0107"> <h3 class="title" id="CD007024-sec-0107">Potential biases in the review process</h3> <p>We searched several databases and performed a systematic search of ongoing clinical trials and unpublished trials on ClinicalTrials.gov and the ICTRP, so we consider the risk of having missed studies is low. However, we included only 13 studies. We were able to assess the risk of publication bias by inspecting the funnel plots for two primary outcomes in the comparison of disulfiram versus placebo or no pharmacological treatment only. Visual inspection of funnel plots did not suggest the presence of publication bias (<a href="#CD007024-fig-0005">Figure 5</a>; <a href="#CD007024-fig-0009">Figure 9</a>). For the other outcomes and comparisons, there were too few studies to assess publication bias with funnel plots. </p> <p>Finally, most studies were published approximately 20 years before this review update (range 1993 to 2016). This could have represented a bias in the quality of reporting, as many studies published before 2000 provide less methodological information and do not have published protocols. </p> </section> <section id="CD007024-sec-0108"> <h3 class="title" id="CD007024-sec-0108">Agreements and disagreements with other studies or reviews</h3> <p>One systematic review published in 2019 showed a worse retention rate of participants treated with disulfiram than those treated with placebo (RR 0.90, 95% CI 0.83 to 0.99; 7 RCTs) and no difference between disulfiram and placebo in the number of participants with three or more consecutive weeks of negative urinalyses (RR 0.96, 95% CI 0.63 to 1.45; 3 RCTs, 296 participants), in line with our finding for continuous abstinence (<a href="./references#CD007024-bbs2-0045" title="ChanB , KondoK , FreemanM , AyersC , MontgomeryJ , KansagaraD . Pharmacotherapy for cocaine use disorder-a systematic review and meta-analysis. Journal of General Internal Medicine2019;34(12):2858-73.">Chan 2019</a>). The numbers of trials and participants in the analyses of <a href="./references#CD007024-bbs2-0045" title="ChanB , KondoK , FreemanM , AyersC , MontgomeryJ , KansagaraD . Pharmacotherapy for cocaine use disorder-a systematic review and meta-analysis. Journal of General Internal Medicine2019;34(12):2858-73.">Chan 2019</a> were lower than those included in our systematic review, and there was considerable heterogeneity in the rate of negative urinalysis (I² = 97%). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007024-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/urn:x-wiley:14651858:media:CD007024:CD007024-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA flow diagram illustrating the study selection process." data-id="CD007024-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_t/tCD007024-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA flow diagram illustrating the study selection process.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/full#CD007024-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007024-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/urn:x-wiley:14651858:media:CD007024:CD007024-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies." data-id="CD007024-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_t/tCD007024-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/full#CD007024-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007024-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/urn:x-wiley:14651858:media:CD007024:CD007024-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD007024-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_t/tCD007024-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/full#CD007024-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007024-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/urn:x-wiley:14651858:media:CD007024:CD007024-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Disulfiram versus placebo or no pharmacological treatment; outcome: 1 Frequency of cocaine use (mean number of days or weeks of cocaine use at the end of treatment)." data-id="CD007024-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_t/tCD007024-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Disulfiram versus placebo or no pharmacological treatment; outcome: 1 Frequency of cocaine use (mean number of days or weeks of cocaine use at the end of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/full#CD007024-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007024-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/urn:x-wiley:14651858:media:CD007024:CD007024-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Funnel plot for comparison: 1 Disulfiram versus placebo or no pharmacological treatment; outcome: 1 Frequency of cocaine use." data-id="CD007024-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_t/tCD007024-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot for comparison: 1 Disulfiram versus placebo or no pharmacological treatment; outcome: 1 Frequency of cocaine use. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/full#CD007024-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007024-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/urn:x-wiley:14651858:media:CD007024:CD007024-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Disulfiram versus placebo or no pharmacological treatment; outcome: 2 Amount of cocaine use (mean weight of cocaine used or money spent on cocaine at the end of treatment)" data-id="CD007024-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_t/tCD007024-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Disulfiram versus placebo or no pharmacological treatment; outcome: 2 Amount of cocaine use (mean weight of cocaine used or money spent on cocaine at the end of treatment) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/full#CD007024-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007024-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/urn:x-wiley:14651858:media:CD007024:CD007024-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Disulfiram versus placebo or no pharmacological treatment; outcome: 3 Continuous abstinence (number of participants who had achieved and maintained abstinence for at least three weeks at the end of treatment)" data-id="CD007024-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-FIG-07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_t/tCD007024-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Disulfiram versus placebo or no pharmacological treatment; outcome: 3 Continuous abstinence (number of participants who had achieved and maintained abstinence for at least three weeks at the end of treatment) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/full#CD007024-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-FIG-07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007024-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/urn:x-wiley:14651858:media:CD007024:CD007024-FIG-08" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Disulfiram versus placebo or no pharmacological treatment; outcome: 4 Point abstinence (number of participants who were abstinent at the end of treatment)." data-id="CD007024-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-FIG-08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_t/tCD007024-FIG-08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Disulfiram versus placebo or no pharmacological treatment; outcome: 4 Point abstinence (number of participants who were abstinent at the end of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/full#CD007024-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-FIG-08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007024-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/urn:x-wiley:14651858:media:CD007024:CD007024-FIG-09" target="_blank"><b></b></a></p> </div><img alt="Funnel plot for comparison: 1 Disulfiram versus placebo or no pharmacological treatment; outcome: 5 Dropout for any reason" data-id="CD007024-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-FIG-09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_t/tCD007024-FIG-09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Funnel plot for comparison: 1 Disulfiram versus placebo or no pharmacological treatment; outcome: 5 Dropout for any reason </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/full#CD007024-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-FIG-09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007024-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/urn:x-wiley:14651858:media:CD007024:CD007024-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Disulfiram versus placebo or no pharmacological treatment, Outcome 1: Frequency of cocaine use" data-id="CD007024-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_t/tCD007024-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Disulfiram versus placebo or no pharmacological treatment, Outcome 1: Frequency of cocaine use </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/references#CD007024-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007024-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/urn:x-wiley:14651858:media:CD007024:CD007024-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Disulfiram versus placebo or no pharmacological treatment, Outcome 2: Amount of cocaine use" data-id="CD007024-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_t/tCD007024-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Disulfiram versus placebo or no pharmacological treatment, Outcome 2: Amount of cocaine use </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/references#CD007024-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007024-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/urn:x-wiley:14651858:media:CD007024:CD007024-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Disulfiram versus placebo or no pharmacological treatment, Outcome 3: Continuous abstinence" data-id="CD007024-fig-0012" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_t/tCD007024-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Disulfiram versus placebo or no pharmacological treatment, Outcome 3: Continuous abstinence </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/references#CD007024-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007024-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/urn:x-wiley:14651858:media:CD007024:CD007024-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Disulfiram versus placebo or no pharmacological treatment, Outcome 4: Point abstinence" data-id="CD007024-fig-0013" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_t/tCD007024-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Disulfiram versus placebo or no pharmacological treatment, Outcome 4: Point abstinence </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/references#CD007024-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007024-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/urn:x-wiley:14651858:media:CD007024:CD007024-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Disulfiram versus placebo or no pharmacological treatment, Outcome 5: Dropout for any reason" data-id="CD007024-fig-0014" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_t/tCD007024-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Disulfiram versus placebo or no pharmacological treatment, Outcome 5: Dropout for any reason </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/references#CD007024-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007024-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/urn:x-wiley:14651858:media:CD007024:CD007024-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Disulfiram versus placebo or no pharmacological treatment, Outcome 6: Dropout due to adverse events" data-id="CD007024-fig-0015" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_t/tCD007024-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Disulfiram versus placebo or no pharmacological treatment, Outcome 6: Dropout due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/references#CD007024-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007024-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/urn:x-wiley:14651858:media:CD007024:CD007024-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Disulfiram versus placebo or no pharmacological treatment, Outcome 7: Any adverse events" data-id="CD007024-fig-0016" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_t/tCD007024-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Disulfiram versus placebo or no pharmacological treatment, Outcome 7: Any adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/references#CD007024-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007024-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/urn:x-wiley:14651858:media:CD007024:CD007024-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Disulfiram versus placebo or no pharmacological treatment, Outcome 8: Individual adverse events" data-id="CD007024-fig-0017" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_t/tCD007024-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Disulfiram versus placebo or no pharmacological treatment, Outcome 8: Individual adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/references#CD007024-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007024-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/urn:x-wiley:14651858:media:CD007024:CD007024-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Disulfiram versus placebo or no pharmacological treatment, Outcome 9: Craving (measured on a visual analogue scale of 0–100 points)" data-id="CD007024-fig-0018" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_t/tCD007024-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Disulfiram versus placebo or no pharmacological treatment, Outcome 9: Craving (measured on a visual analogue scale of 0–100 points) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/references#CD007024-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007024-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/urn:x-wiley:14651858:media:CD007024:CD007024-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Disulfiram versus placebo or no pharmacological treatment, Outcome 10: Depression (measured on a scale of 0–52 points)" data-id="CD007024-fig-0019" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_t/tCD007024-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Disulfiram versus placebo or no pharmacological treatment, Outcome 10: Depression (measured on a scale of 0–52 points) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/references#CD007024-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007024-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/urn:x-wiley:14651858:media:CD007024:CD007024-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Disulfiram versus placebo or no pharmacological treatment, Outcome 11: Anxiety (measured on a scale of 0–56 points)" data-id="CD007024-fig-0020" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_t/tCD007024-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Disulfiram versus placebo or no pharmacological treatment, Outcome 11: Anxiety (measured on a scale of 0–56 points) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/references#CD007024-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007024-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/urn:x-wiley:14651858:media:CD007024:CD007024-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Disulfiram versus naltrexone, Outcome 1: Frequency of cocaine use" data-id="CD007024-fig-0021" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_t/tCD007024-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Disulfiram versus naltrexone, Outcome 1: Frequency of cocaine use</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/references#CD007024-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007024-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/urn:x-wiley:14651858:media:CD007024:CD007024-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Disulfiram versus naltrexone, Outcome 2: Amount of cocaine use" data-id="CD007024-fig-0022" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_t/tCD007024-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Disulfiram versus naltrexone, Outcome 2: Amount of cocaine use</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/references#CD007024-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007024-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/urn:x-wiley:14651858:media:CD007024:CD007024-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Disulfiram versus naltrexone, Outcome 3: Dropout for any reason" data-id="CD007024-fig-0023" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_t/tCD007024-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Disulfiram versus naltrexone, Outcome 3: Dropout for any reason</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/references#CD007024-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007024-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/urn:x-wiley:14651858:media:CD007024:CD007024-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Disulfiram versus naltrexone, Outcome 4: Dropout due to adverse events" data-id="CD007024-fig-0024" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_t/tCD007024-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Disulfiram versus naltrexone, Outcome 4: Dropout due to adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/references#CD007024-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007024-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/urn:x-wiley:14651858:media:CD007024:CD007024-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Disulfiram versus naltrexone, Outcome 5: Individual adverse events" data-id="CD007024-fig-0025" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_t/tCD007024-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Disulfiram versus naltrexone, Outcome 5: Individual adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/references#CD007024-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007024-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/urn:x-wiley:14651858:media:CD007024:CD007024-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Disulfiram versus naltrexone, Outcome 6: Craving (measured on a visual analogue scale of 0–100 points)" data-id="CD007024-fig-0026" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_t/tCD007024-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Disulfiram versus naltrexone, Outcome 6: Craving (measured on a visual analogue scale of 0–100 points) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/references#CD007024-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007024-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/urn:x-wiley:14651858:media:CD007024:CD007024-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Disulfiram versus naltrexone, Outcome 7: Depression (measured on a scale of 0–52 points)" data-id="CD007024-fig-0027" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_t/tCD007024-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Disulfiram versus naltrexone, Outcome 7: Depression (measured on a scale of 0–52 points) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/references#CD007024-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007024-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/urn:x-wiley:14651858:media:CD007024:CD007024-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Disulfiram versus naltrexone, Outcome 8: Anxiety (measured on a scale of 0–56 points)" data-id="CD007024-fig-0028" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_t/tCD007024-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Disulfiram versus naltrexone, Outcome 8: Anxiety (measured on a scale of 0–56 points) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/references#CD007024-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007024-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/urn:x-wiley:14651858:media:CD007024:CD007024-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Disulfiram versus placebo or no pharmacological treatment (subgroup analyses), Outcome 1: Frequency of cocaine use (according to the presence of alcohol dependence)" data-id="CD007024-fig-0029" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_t/tCD007024-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Disulfiram versus placebo or no pharmacological treatment (subgroup analyses), Outcome 1: Frequency of cocaine use (according to the presence of alcohol dependence) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/references#CD007024-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007024-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/urn:x-wiley:14651858:media:CD007024:CD007024-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Disulfiram versus placebo or no pharmacological treatment (subgroup analyses), Outcome 2: Frequency of cocaine use (according to the presence of opioid dependence in opioid agonist treatment)" data-id="CD007024-fig-0030" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_t/tCD007024-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Disulfiram versus placebo or no pharmacological treatment (subgroup analyses), Outcome 2: Frequency of cocaine use (according to the presence of opioid dependence in opioid agonist treatment) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/references#CD007024-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007024-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/urn:x-wiley:14651858:media:CD007024:CD007024-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Disulfiram versus placebo or no pharmacological treatment (subgroup analyses), Outcome 3: Dropout for any reason (according to the presence of comorbid alcohol dependence)" data-id="CD007024-fig-0031" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_t/tCD007024-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Disulfiram versus placebo or no pharmacological treatment (subgroup analyses), Outcome 3: Dropout for any reason (according to the presence of comorbid alcohol dependence) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/references#CD007024-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007024-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/urn:x-wiley:14651858:media:CD007024:CD007024-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Disulfiram versus placebo or no pharmacological treatment (subgroup analyses), Outcome 4: Dropout for any reason (according to the presence of opioid dependence in opioid agonist treatment)" data-id="CD007024-fig-0032" src="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_t/tCD007024-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Disulfiram versus placebo or no pharmacological treatment (subgroup analyses), Outcome 4: Dropout for any reason (according to the presence of opioid dependence in opioid agonist treatment) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/references#CD007024-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/media/CDSR/CD007024/image_n/nCD007024-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007024-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table – disulfiram compared to placebo or no pharmacological treatment for people with cocaine dependence</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Disulfiram compared to placebo or no pharmacological treatment for people with cocaine dependence</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> people with cocaine dependence<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> disulfiram<br/><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(datasets; studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo or no treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with disulfiram</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Frequency of cocaine use</b> (mean number of days or weeks of cocaine use at the end of treatment) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>SMD 0.11 SDs lower</b><br/>(0.39 lower to 0.17 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>818<br/>(13 datasets; 9 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Amount of cocaine use</b> (mean weight of cocaine used or money spent on cocaine at the end of treatment) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>SMD 0 SDs</b><br/>(0.3 lower to 0.3 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>376<br/>(7 datasets; </p> <p>5 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Continuous abstinence from cocaine</b> (number of participants who had achieved and maintained abstinence for at least three weeks at the end of treatment) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>245 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>301 per 1000</b><br/>(196 to 467) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.23</b><br/>(0.80 to 1.91) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>386<br/>(6 datasets; </p> <p>5 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Point abstinence</b> (number of participants who were abstinent at the end of the treatment) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>309 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>488 per 1000</b><br/>(324 to 729) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.58</b><br/>(1.05 to 2.36) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142<br/>(3 datasets; </p> <p>2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dropout for any reason</b> (number of participants who did not complete treatment) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>273 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>328 per 1000</b><br/>(251 to 423) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.20</b><br/>(0.92 to 1.55) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>841<br/>(14 datasets; </p> <p>10 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dropout due to adverse events</b> (number of participants who did not complete treatment due to adverse events) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 12.97</b><br/>(0.77 to 218.37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/>(1 dataset; </p> <p>1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any adverse events</b> (number of participants who experienced at least one adverse event) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>67 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b><br/>(23 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.00</b><br/>(0.35 to 25.68) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 dataset; </p> <p>1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>e</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SD:</b> standard deviation; <b>SMD:</b> standardised mean difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level for risk of bias (all or most studies at unclear risk of bias for allocation concealment) and one level for inconsistency (I<sup>2</sup> = 72%; Chi<sup>2</sup> = 89.2%, P = 0.002).<br/><sup>b</sup> Downgraded one level for risk of bias (all or most studies at unclear risk of bias for allocation concealment) and one level for imprecision (fewer than 400 participants).<br/><sup>c</sup> Downgraded one level for risk of bias (all or most studies at unclear risk of bias for allocation concealment) and one level for imprecision (optimal information size not met).<br/><sup>d</sup> Downgraded one level for risk of bias (unclear risk of selection bias) and two levels for imprecision (single study with 67 participants).<br/><sup>e</sup> Downgraded one level for risk of bias (unclear risk of selection bias) and two levels for imprecision (single study with 30 participants). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table – disulfiram compared to placebo or no pharmacological treatment for people with cocaine dependence</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/full#CD007024-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007024-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings table – disulfiram compared to naltrexone for people with cocaine dependence</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Disulfiram compared to naltrexone for people with cocaine dependence</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> people with cocaine dependence<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> disulfiram<br/><b>Comparison:</b> naltrexone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Naltrexone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Disulfiram</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Frequency of cocaine use</b> (mean number of days or weeks of cocaine use at the end of treatment) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean frequency of cocaine use was <b>0 days</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 1.9 days fewer</b><br/>(3.37 fewer to 0.43 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Amount of cocaine use</b> (mean weight of cocaine used or money spent on cocaine at the end of treatment) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>SMD 0.12 SDs higher</b><br/>(0.27 lower to 0.51 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Continuous abstinence from cocaine</b> (number of participants who had achieved and maintained abstinence for at least three weeks at the end of treatment) </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Point abstinence</b> (number of participants who were abstinent at the end of the treatment) </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dropout for any reason</b> (number of participants who did not complete treatment) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>415 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>357 per 1000</b><br/>(233 to 548) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.86</b><br/>(0.56 to 1.32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dropout due to adverse events</b> (number of participants who did not complete treatment due to adverse events) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>250 per 1000</b><br/>(35 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.50</b><br/>(0.07 to 3.55) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any adverse events</b> (number of participants who experienced at least one adverse event) </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SD:</b> standard deviation; <b>SMD:</b> standardised mean difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level for risk of bias (both studies at unclear risk of selection bias) and one level for imprecision (fewer than 400 participants).<br/><sup>b</sup> Downgraded one level for risk of bias (two studies at high risk of performance and detection bias; all three studies at unclear risk of selection bias) and two levels for imprecision (fewer than 100 events). <br/><sup>c</sup> Downgraded one level for risk of bias (unclear risk of selection bias) and two levels for imprecision (fewer than 100 events). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings table – disulfiram compared to naltrexone for people with cocaine dependence</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/full#CD007024-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007024-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Disulfiram versus placebo or no pharmacological treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Frequency of cocaine use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>818</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.11 [‐0.39, 0.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>728</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.22 [‐0.50, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Versus no pharmacological treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.14, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Amount of cocaine use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.30, 0.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.30, 0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Continuous abstinence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.80, 1.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.57, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Versus no pharmacological treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.87 [1.09, 3.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Point abstinence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.58 [1.05, 2.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.58 [1.05, 2.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Dropout for any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>841</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.92, 1.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>833</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.90, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Versus no pharmacological treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.76, 11.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Dropout due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.97 [0.77, 218.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.97 [0.77, 218.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Any adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.35, 25.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.35, 25.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Individual adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.92, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 Drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.93, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.3 Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.83, 2.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.4 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.61, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.5 Decreased sexual desire</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.65, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.6 Increased sexual desire</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.17, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.7 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.41, 2.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.8 Skin rush</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [0.57, 4.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.9 Difficulty achieving orgasm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.83 [0.66, 5.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.10 Toothache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.51, 3.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.11 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.61, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.12 Slurred Speech</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.13, 68.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Craving (measured on a visual analogue scale of 0–100 points) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐25.00 [‐44.52, ‐5.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Versus no pharmacological treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐25.00 [‐44.52, ‐5.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Depression (measured on a scale of 0–52 points) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.00 [‐4.13, 2.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 Versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.00 [‐4.13, 2.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Anxiety (measured on a scale of 0–56 points) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.50 [‐4.78, 1.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 Versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.50 [‐4.78, 1.78]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Disulfiram versus placebo or no pharmacological treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/references#CD007024-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007024-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Disulfiram versus naltrexone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Frequency of cocaine use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.90 [‐3.37, ‐0.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Amount of cocaine use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [‐0.27, 0.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Dropout for any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.56, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Dropout due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.07, 3.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Individual adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.81, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.2 Drowsiness/fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.67, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.3 Anxiety/irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.81, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.4 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.67, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.5 Upper respiratory tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.75, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.6 Decreased sexual desire</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.62, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.7 Increased sexual desire</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.23, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.8 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.34, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.9 Skin rush</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [0.63, 6.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.10 Difficulty achieving orgasm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.51, 3.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.11 Toothache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.31, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.12 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.72 [0.53, 5.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Craving (measured on a visual analogue scale of 0–100 points) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.02 [‐16.73, 14.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Depression (measured on a scale of 0–52 points) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.00 [‐4.76, 0.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Anxiety (measured on a scale of 0–56 points) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.00 [‐4.27, 2.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Disulfiram versus naltrexone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/references#CD007024-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007024-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Disulfiram versus placebo or no pharmacological treatment (subgroup analyses)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Frequency of cocaine use (according to the presence of alcohol dependence) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>641</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.42, 0.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 With comorbid alcohol dependence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [‐0.18, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 Without comorbid alcohol dependence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.60 [‐2.56, ‐0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.3 Mix of participants with and without alcohol dependence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.30, 0.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Frequency of cocaine use (according to the presence of opioid dependence in opioid agonist treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>719</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.46, 0.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 With comorbid opioid dependence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.35 [‐0.78, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 Without comorbid opioid dependence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.44, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Dropout for any reason (according to the presence of comorbid alcohol dependence) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>664</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.87, 1.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 With comorbid alcohol dependence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.22, 5.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 Without comorbid alcohol dependence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.30, 3.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.3 With intermediate comorbid alcohol dependence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.97, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Dropout for any reason (according to the presence of opioid dependence in opioid agonist treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>742</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.90, 1.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 With comorbid opioid dependence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>597</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [1.05, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.2 Without comorbid opioid dependence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.21, 2.79]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Disulfiram versus placebo or no pharmacological treatment (subgroup analyses)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007024.pub3/references#CD007024-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007024.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD007024-note-0016">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007024-note-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD007024-note-0014">Français</a> </li> <li class="section-language"> <a class="" href="id#CD007024-note-0013">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="ja#CD007024-note-0011">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD007024-note-0007">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD007024-note-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD007024-note-0015">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD007024-note-0008">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD007024-note-0006">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD007024-note-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD007024-note-0005">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007024\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007024\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007024\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007024\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007024\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007024\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007024\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007024\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007024\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007024\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007024\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007024\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007024\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007024\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007024\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007024\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007024\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007024\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=qy4lqFNF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007024.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007024.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007024.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007024.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007024.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728930069"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007024.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728930073"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007024.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ed07bbe539368',t:'MTc0MDcyODkzMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 